Method for determining the extent of oxidative degradation of polysorbate 20 in aqueous formulations
Polyethylene glycol-6-laurate is used as a marker in LC-MS to detect and quantify oxidative degradation of polysorbate 20, addressing the lack of effective monitoring methods and ensuring the stability of aqueous formulations, particularly biopharmaceuticals.
Patent Information
- Application Number
- JP2024534709
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-12-20
- Filing Date
- 2022-12-19
- Publication Date
- 2024-11-28
- Estimated Expiration
- 2042-12-19
AI Technical Summary
Current analytical methods fail to effectively identify and quantify oxidative degradation products of polysorbate 20 in aqueous formulations, particularly in biopharmaceutical applications, lacking specific marker substances for oxidative degradation and effective monitoring tools.
The method involves using polyethylene glycol-6-laurate as a marker substance for oxidative degradation of polysorbate 20, employing liquid chromatography-mass spectrometry (LC-MS) to separate, detect, and quantify this marker in aqueous formulations, allowing for the determination of the degree of oxidative degradation.
This approach enables accurate monitoring and quantification of oxidative degradation in polysorbate 20, distinguishing between oxidative and non-oxidative degradation pathways, and providing insights into the stability and quality of aqueous formulations, especially biopharmaceuticals.
Smart Images

Figure 2024544257000001_ABST
Abstract
Description
[Technical field]
[0001] The present invention relates to a method for determining the extent of oxidative degradation of Polysorbate 20 in an aqueous formulation. [Background technology]
[0002] Polysorbates (PS) constitute a group of non-ionic surfactants and are widely used as wetting or emulsifying agents, for example in cosmetics, medicines, foods, cleaning agents and detergents. Due to their biocompatibility and low toxicity, polysorbates are the most widely used surfactants for biopharmaceutical formulations and function as excipients in biopharmaceutical formulations to solubilize substances such as proteins that are not water-soluble per se in water. In particular, they stabilize proteins against interfacial tension forces and prevent interface-induced aggregation or surface adsorption. In this way, they help stabilize ingredients, such as proteins, in aqueous formulations, thus maintaining the activity and efficacy of the ingredients. Polysorbates are derived from a core structure of sorbitan or isosorbide linked to poly(oxy)ethylene (POE) chains of variable length, which can then be esterified with fatty acids. Illustrative representatives of polysorbates are: Polysorbate 20 (PS20) or polyoxyethylene (20) sorbitan monolaurate; Polysorbate 40 (PS40) or polyoxyethylene (20) sorbitan monopalmitate; Polysorbate 60 (PS60) or polyoxyethylene (20) sorbitan monostearate; and Polysorbate 80 (PS80) or Polyoxyethylene (20) Sorbitan Monooleate It is.
[0003] The numbers 20, 40, 60, and 80 following the term "polysorbate" represent the type of fatty acid associated with the polyoxyethylene sorbitan residue of the molecule, i.e., monolaurate is designated by 20, monopalmitate by 40, monostearate by 60, and monooleate by 80. The number 20 following the term "polyoxyethylene" represents the number of oxyethylene-(CH 2 CH 2 Commercially available polysorbates usually consist of a mixture of structurally related molecules, such as unesterified sorbitan and / or isosorbitan-polyethylene glycol (PEG) species, mono-, di-, tri-, tetra-esters, fatty acids, etc. The two main polysorbates, polysorbate 20 (PS20) and polysorbate 80 (PS80), which are most relevant in biopharmaceutical preparations, differ mainly in the distribution of fatty acid and poly(oxy)ethylene chain elements, while polysorbates 40 and 60 are more commonly used in the food or cosmetic industries. Polysorbates exhibit several degradation reactions, which lead to the formation of numerous degradation products, which can lead to loss of functional properties and potentially to instability of the aqueous formulations in which they are used. Thus, the degradation of polysorbates can lead to particle formation in aqueous formulations, which can be a major quality issue and a potential risk factor.
[0004] For the degradation of polysorbates, observed for example in biopharmaceutical products, there are two main degradation pathways: hydrolysis, which is typically catalyzed by impurities of the host cell and represents ester hydrolysis, leading to the liberation of free fatty acids, and oxidative degradation, also called autoxidation, which is initiated by free radicals. As is commonly known, autoxidation can occur anywhere in the molecule, as long as the kinetic characteristics of H extraction at a given site are favorable. In the present context, it must be taken into account that for a complex molecule such as polysorbate 20, there can generally be a great number of degradation products that can be detected by several different analytical techniques. In [1, 2], for example, about 60 different species are envisaged. Although the autoxidation of unsaturated fatty acids, especially oleic acid, has been extensively studied for decades due to its importance in the oxidation of lipids in foods and oils, little is known about the actual degradation pathways and stability of the individual components of polysorbates under oxidative stress.
[0005] The oxidative degradation of both polysorbate 20 and polysorbate 80 has already been described in the literature. These references aim to describe the mechanism of oxidative degradation occurring either along the unsaturated fatty acid structure where double bonds are present [1] or within the poly(oxy)ethylene chain structure [2], both agents being susceptible to free radical-induced fragmentation.
[0006] For polysorbate 80, the first pathway is prevalent due to the presence of oleic acid containing its double bond. Thus, specific individual components resulting from oxidative degradation are identified that appear during degradation and represent different substructures that can be detected by LC-MS (liquid chromatography-mass spectrometry) analysis. Such individual components are also called oxidation markers. For example, in [1], the main degradation products of polysorbate 20 and polysorbate 80 are evaluated in oxidative stress induced by 2,2'-azobis-2-methyl-propanimidamide, dihydrochloride (AAPH). AAPH is a water-soluble azo compound used as a model oxidant and free radical generator. The oxidative markers of polysorbate 80 found include poly(oxy)ethylenesorbitan esterified with several structures, such as hydroperoxy-oleate (hydroperoxy-C18:1), keto-oleate (keto-C18:1), hydroxyl-oleate (hydroxyl-C18:1), epoxy-stearate (epoxy-C18:0), and oxo-nonanoate (oxo-C9:0), and are described including the mass-to-charge ratio (m / z) of the respective ions used in mass spectrometry to enable their analysis by LC-MS based detection.
[0007] For polysorbate 20, with the loss of unsaturated fatty acids, the oxidative degradation of polysorbates proceeds mainly via the fragmentation of ether bonds within the poly(oxy)ethylene structure [2], which does not necessarily result in the emergence of novel structures that can be used as marker structures. Thus, the current literature has not yet described any oxidizable marker structures for liquid chromatography-mass spectrometry (LC-MS)-based analysis targeting the poly(oxy)ethylene substructure region.
[0008] According to Borisov et al. [1], poly(oxy)ethylene esters containing 4-5 oxy-ethylene (OE) units are proposed to be the by-products of oxidative degradation. Kishore et al. [2] describe poly(oxy)ethylene esters containing 1-6 oxy-ethylene units. Zhang et al. [3] describe the formation of poly(oxy)ethylene esters containing 1-8 ethylene oxide (EO) units (POE-laurates), a mixture in which POE-laurates containing 6 EO units predominate, when the solution is 0.1% in the simultaneous presence of L-histidine and polysorbate 20. 2 The first was under forced oxidative conditions, further saturated with gas. However, none of these studies provide chemical structures and corresponding mass-to-charge ratios (m / z ratios) of ions that allow detection and analysis via methods based on liquid chromatography-mass spectrometry (LC-MS). The above mentioned literature demonstrates that all poly(oxy)ethylene-laurates, e.g. those with 1-8 oxy-ethylene units, arise from oxidative stress, starting from polysorbate 20, which is used as the stressed substance. This typically cannot be transferred to aqueous formulations under ambient conditions, and is especially not applicable to biopharmaceutical formulations. In practice, this is not a viable approach to implement.
[0009] More importantly, the degradation products were artificially generated using substances to generate free radicals, which are far from the real situation and conditions of normal aqueous formulations. Moreover, the reality in, for example, natural biopharmaceutical formulations, for example, under routine stabilization conditions, was not taken into account. Moreover, the degradation products were not related to the oxidative degradation of polysorbates without the use of artificial radical initiators. In addition, none of the degradation products were related to the mass-to-charge ratio (m / z ratio) of ions that would allow monitoring via a method based on liquid chromatography-mass spectrometry (LC-MS). In addition to label-free analyses based on liquid chromatography-mass spectrometry (LC-MS), the oxidative degradation of polysorbates has been investigated using other techniques. For example, the use of 2,4-dinitrophenylhydrazine for the derivatization of free fatty acid esters arising as by-products of oxidative stress applied to polysorbate 20 has been described [4], while charged aerosol detection coupled to reversed-phase chromatography has been used [5]. However, these techniques do not reveal the individual degradation species of polysorbates under oxidative stress.
[0010] However, polysorbate degradation is a major challenge, especially in biopharmaceutical development, and can be a significant risk to successful product development, for example by deteriorating product quality or increasing safety issues. Therefore, understanding the causes and processes of polysorbate degradation is important to formulate suitable treatment strategies. According to the current state of the art, it is not possible to differentiate between hydrolysis and oxidative degradation of polysorbates by direct and unambiguous analytical tools, and in particular no substance is known to identify the presence of oxidative modification of polysorbate 20, i.e. no marker substance is known to originate from the oxidative degradation of polysorbate 20, which is widely used as a surfactant in aqueous formulations. Moreover, to date, no analytical method has been described to detect and quantify such marker substances in aqueous formulations, especially in biopharmaceutical formulations.
[0011] Furthermore, the liquid chromatography mass spectrometry (LC-MS) method disclosed, for example, in [1] is not intended as a method for absolute quantification of fatty acid esters in polysorbates and only allows semi-quantitative determination using this method. Furthermore, a method to study the mechanism of polysorbate (PS) degradation is disclosed in
[13] . Ultra-performance liquid chromatography-mass spectrometry (UPLC-MS) was used to 18 It was used to characterize polysorbate 20 and its degradation products by measuring O incorporation, and the two main so-called degradation products were free lauric acid and polyoxyethylene (POE) laurate.
[0012] According to
[14] , a process for quantifying at least one polysorbate derivative in a sample is provided, comprising: - performing an LC-MS analysis of the sample based on the signal from the dioxolanylium ion; - carrying out an internal calibration with an internal standard of polysorbate The present invention provides a process comprising: an internal standard refers to a chemical compound that is added to samples, blanks and calibration standards in a certain amount in chemical analysis. It is a compound that is generally very similar to, but not identical to, polysorbate in samples. In one embodiment, the internal standard (IS) can be selected from compounds that have a polyethylene glycol chain esterified with one or more carboxylic acids to have physicochemical properties similar to polysorbate.
[15] describes a method for mitigating polysorbate degradation in an aqueous formulation containing polysorbate, comprising adding a cyclodextrin to the formulation, wherein the resulting mass ratio of cyclodextrin to polysorbate is greater than about 37.5:1.
[0013] Indeed, the patent and academic literature as a whole is completely silent on the use of specific marker substances, especially unlabeled oxidation marker species, that are specific for polysorbate 20 and specifically related to naturally occurring oxidative polysorbate degradation. Moreover, to date, no oxidation by-products have been identified as established markers to track the oxidation of polysorbate 20 in aqueous formulations containing polysorbate 20, especially biopharmaceutical formulations that contain biological APIs (active pharmaceutical ingredients) and conventional excipients. It is therefore an object of the present invention to overcome at least these problems of the prior art and to provide a method by which marker substances, in particular unlabeled oxidation marker species, specific for polysorbate 20, particularly related to the oxidative degradation of polysorbate 20, can be identified and determined. The method should make it possible to monitor and quantify the substances of oxidation markers in aqueous formulations. Summary of the Invention
[0014] Surprisingly, it has been found that a specific marker substance, namely polyethylene glycol-6-laurate (PEG-6-laurate), is associated with the oxidative degradation pathway of polysorbate 20, since this marker substance is formed during the oxidative degradation of polysorbate 20. This marker substance allows the extent of oxidative degradation of polysorbate 20 to be determined in aqueous formulations by analytical methods, since the relative levels of said marker substance indicate that oxidative degradation occurs.
[0015] Accordingly, there is provided a (first) method (in a first alternative) for determining the extent of oxidative degradation of polysorbate 20 in an aqueous formulation containing polysorbate 20, comprising the following steps: Step 1 of preparing a first sample of the aqueous formulation to be tested, which serves as a reference sample; Step 2 of preparing a second sample of the aqueous formulation to be tested and any further samples; using a liquid chromatography-mass spectrometry based method to separate polyethylene glycol-6-laurate and determine the peak area of polyethylene glycol-6-laurate, an oxidation marker of oxidative degradation of polysorbate 20, from each of the reference sample of step 1 and the second sample and any further samples of step 2; determining a relative peak area of polyethylene glycol-6-laurate based on the peak area of polyethylene glycol-6-laurate of the second sample and each of any further samples relative to the peak area of polyethylene glycol-6-laurate of the reference sample, the relative peak area being proportional to the extent of oxidative degradation of polysorbate 20; and Step 4. Quantify the amount of polyethylene glycol-6-laurate in the second sample and each of the optional further samples based on the relative peak areas of each sample. The present invention provides a method comprising:
[0016] According to one embodiment, the relative peak area of polyethylene glycol-6-laurate for the second sample and each of the optional further samples in step 3 is: - calculating the obtained peak area difference by subtracting the polyethylene glycol-6-laurate peak area of the reference sample from the polyethylene glycol-6-laurate peak area of the second sample and from the polyethylene glycol-6-laurate peak area of each of any further samples, respectively; or - normalizing the obtained peak areas, by setting the peak area of polyethylene glycol-6-laurate of the reference sample to 100% and calculating and normalizing the peak areas of polyethylene glycol-6-laurate of each of the second sample and any further samples, respectively, based thereon. is determined by.
[0017] Thus, the method of the invention provides the identification of polyethylene glycol-6-laurate as a by-product of the oxidative degradation of polysorbate 20 in aqueous formulations containing polysorbate 20, and allows this marker substance to be separated, detected and determined with respect to a reference by a liquid chromatography mass spectrometry based method (LC-MS based method) and may be quantified in the aqueous formulation by a specific analytical method. The relative peak areas, known to be proportional to the concentration of the analyte (integral), allow the relative peak areas of polyethylene glycol-6-laurate to be correlated with the degree of oxidative degradation of polysorbate 20.
[0018] In a first alternative of the (first) method above, a first sample of the aqueous formulation to be tested is taken as a reference sample. In an alternative embodiment, an externally generated or provided reference sample is used as a reference, ie, an external reference sample is independently provided. Thus, according to another embodiment, there is provided a (first) method (in a second alternative) for determining the degree of oxidative degradation of polysorbate 20 in an aqueous formulation containing polysorbate 20, comprising the following steps: Step 1' of preparing a reference sample, which is an aqueous solution containing polysorbate 20 and has the same content of polysorbate 20 as the aqueous formulation to be tested; a step 2' of preparing a first sample of the aqueous formulation to be tested and any further samples; using a liquid chromatography-mass spectrometry based method for separating polyethylene glycol-6-laurate and determining the peak area of polyethylene glycol-6-laurate, an oxidation marker of oxidative degradation of polysorbate 20, from the reference sample of step 1' and the first sample and each of any further samples of step 2', respectively; determining a relative peak area of polyethylene glycol-6-laurate based on the peak area of polyethylene glycol-6-laurate of the first sample and each of any further samples relative to the peak area of polyethylene glycol-6-laurate of a reference sample, the relative peak area being proportional to the extent of oxidative degradation of polysorbate 20; and Step 4' may quantify the amount of polyethylene glycol-6-laurate in the first sample and each of the optional further samples based on the relative peak areas of each sample. The present invention provides a method comprising:
[0019] According to one embodiment, the relative peak area of polyethylene glycol-6-laurate for the first sample and each of any further samples in step 3' is - calculating the obtained peak area difference by subtracting the polyethylene glycol-6-laurate peak area of the reference sample from the polyethylene glycol-6-laurate peak area of the first sample and from the polyethylene glycol-6-laurate peak area of each of any further samples, respectively; or - normalizing the obtained peak areas, by setting the peak area of polyethylene glycol-6-laurate of the reference sample to 100% and calculating and normalizing the peak areas of polyethylene glycol-6-laurate of each of the first sample and any further samples, respectively, based thereon. is determined by.
[0020] In one embodiment of the invention, in step 2 or step 2', several samples of the aqueous formulation containing polysorbate 20 can be taken at successive times T1, T2, T3... to determine not only random samples in the aqueous formulation over time, but also possible oxidative degradation pathways of polysorbate 20. For example, in step 2, two, three or more further samples of the aqueous formulation containing polysorbate 20 can be taken at successive time intervals T1, T2, T3... which can be of the same or different length.
[0021] In the first method above (first and second alternatives), one aqueous formulation was tested for oxidative degradation of polysorbate 20. However, several aqueous formulations can also be examined. Thus, in a further embodiment of the invention, a method comprising the steps of: Step 1a of preparing a sample of each aqueous formulation to be tested; using a liquid chromatography and mass spectrometry based method to separate polyethylene glycol-6-laurate and determine the peak area of polyethylene glycol-6-laurate, an oxidation marker of the oxidative degradation of polysorbate 20, from each sample of step 1a; Step 2a of comparing the peak areas of the samples with each other, the difference in the peak areas of the samples (relative peak areas) being proportional to the degree of oxidative degradation of polysorbate 20 in each respective sample; and The amount of polyethylene glycol-6-laurate in each sample may be quantified based on the peak area obtained for each sample. Step 3a provides a (second) method for determining the extent of oxidative degradation of polysorbate 20 in several aqueous formulations, e.g., two, three, four or more aqueous formulations, each containing polysorbate 20, in particular where each aqueous formulation contains the same amount of polysorbate 20.
[0022] In this (second) method of the present invention, peak areas can be directly compared with each other, or it is also possible to use a reference to determine relative peak areas, and then compare the sample with the reference.The reference can be one of the samples taken, so that the selection of the sample that can be used as reference depends on each individual case.The reference can also be an external reference sample, as already described in connection with the first method.
[0023] In a (second) method, the relative peak area of polyethylene glycol-6-laurate for each sample can be determined relative to a reference sample, the procedure comprising: - calculating the difference in the obtained peak areas by subtracting the peak area of polyethylene glycol-6-laurate of the reference sample from the peak area of polyethylene glycol-6-laurate of each sample of step 2a, respectively; or - normalizing the obtained peak areas, by setting the peak area of polyethylene glycol-6-laurate of the reference sample to 100%, and calculating and normalizing the peak area of polyethylene glycol-6-laurate of each sample of step 2a based thereon; It is executed by:
[0024] The separation of polyethylene glycol-6-laurate, identified as an oxidative marker substance of the oxidative degradation of polysorbate 20, is achieved by liquid chromatography as part of a liquid chromatography-mass spectrometry based method by using its hydrophobicity. In a subsequent mass spectrometry procedure, the molecules to be examined are transferred to the gas phase and ionized. The molecules may be fragmented in this manner. Thus, the detection and determination of the relative levels of polyethylene glycol-6-laurate in step 3, step 3' or step 2a is performed using a liquid chromatography-mass spectrometry based method. Any quantification in step 4, step 4' or step 3a may be performed with external calibration, for example using a standard solution of polyethylene glycol-6-laurate. According to one embodiment of the liquid chromatography mass spectrometry based method, liquid chromatography is used as separation chromatography, especially in the form of column chromatography, more particularly as reversed phase chromatography. In a further embodiment, the liquid chromatography as part of the liquid chromatography mass spectrometry based method is high performance liquid chromatography (HPLC). Ultra performance liquid chromatography (UPLC) can also be used. According to one embodiment of the liquid chromatography-mass spectrometry based method, gradient elution is used.
[0025] In another embodiment, a polar solvent is added to the polysorbate-containing sample to be investigated before performing liquid chromatography, in particular a solvent used in liquid chromatography. In a further embodiment, the mass spectrometry method as part of the liquid chromatography-mass spectrometry based method is selected to be high resolution mass spectrometry (HR-MS), which can be used in particular for structure elucidation and is advantageous for this purpose. According to one embodiment, for data evaluation of the liquid chromatography mass spectrometry based method of the present invention, an extracted ion chromatogram is generated from a mass to charge ratio range including about 487 amu, in particular including or consisting of the range of 486.5 to 487.5 amu.
[0026] An optional additional step 5, which may follow step 4 or step 3, or an optional additional step 5', which may follow step 4' or step 3', or an optional additional step 4a, which may follow step 3a or step 2a, comprises estimating to what extent polysorbate 20 has already been oxidatively degraded in the sample based on the inverse relationship between the levels of polyethylene glycol-6-laurate and polysorbate 20. It was found that the decrease in the content of polysorbate 20 in the sample and hence in the aqueous formulation clearly correlates with the increase in the relative level of the oxidative marker substance polyethylene glycol-6-laurate, with increasing amounts of polysorbate 20.
[0027] According to a further embodiment of the invention, the aqueous formulation contains one or more proteins. The proteins may be selected from monoclonal antibodies, polyclonal antibodies, monospecific antibodies, multispecific antibodies, single chain antibodies or antibody fragments thereof, such as Fv, scFv, Fab, Fab', scFab, F(ab')2, Fab2, Fc and Fc' fragments, heavy and light immunoglobulin chains and their constant, variable or hypervariable regions and Fv and Fd fragments, bispecific antibodies, trispecific antibodies, scFv-Fc, minibodies, or single domain antibodies, or mixtures thereof. The proteins may be selected from therapeutic proteins used for the prevention or treatment of diseases or disorders. According to another embodiment, the aqueous formulation may be an aqueous pharmaceutical formulation, in particular an aqueous biopharmaceutical formulation, containing polysorbate 20. For example, the aqueous biopharmaceutical formulation may contain a pharmaceutical acceptable polysorbate 20, optionally an API, such as one or more proteins, and any pharmaceutical acceptable excipients used in the prevention or treatment of a disease or disorder. The present polysorbate 20 may be intended for pharmaceutical use, in particular for use in medicine. In particular, the polysorbate 20 may be pharmaceutically acceptable and have pharmaceutical grade quality, such as European / US / Chinese Pharmacopoeia pharmaceutical grade quality. For example, the polysorbate 20 may be suitable for parenteral administration. The following commercial products of polysorbate 20 are exemplary mentioned: Super Refined™ PS20, Tween™ 20, Tween™ 20 HP, Tween™ 20 Pharmaceutical Grade or PS20 HP, available in particular from Croda, Edison, NJ, USA or Croda Europe Ltd., or PS20 China Grade, available in particular from Nanjing Well Pharmaceutical Co., Ltd.
[0028] The present invention also relates to a process for producing a recombinant protein (third method), comprising the steps of: a) culturing in a cell culture a eukaryotic cell expressing the recombinant protein; b) harvesting the recombinant protein; c) purifying the recombinant protein using the aqueous formulation; and (d) formulating the recombinant protein into a pharma- ceutically acceptable aqueous formulation suitable for administration using polysorbate 20; and step e) of obtaining at least one sample of the pharma- ceutically acceptable aqueous formulation of step d); Including, The process (third method) further comprises carrying out the (first or second) method for determining the degree of oxidative degradation of polysorbate 20 disclosed in the present invention on the sample obtained in step e).
[0029] According to a further embodiment, the process for producing a recombinant protein (third method) comprises obtaining at least one sample containing the recombinant protein and polysorbate 20 in step e) as described above, wherein the sample from step d) is a drug substance sample or a drug product sample. The present invention is also directed to a method for determining the degree of oxidative degradation of polysorbate 20 in an aqueous formulation or several aqueous formulations each containing polysorbate 20, in particular the use of polyethylene glycol-6-laurate as an oxidation marker in the (first or second) method disclosed herein. A further object of the present invention is the use of the (first or second) method disclosed herein as a stability test during the development, manufacture, shelf-life or storage of an aqueous formulation or several aqueous formulations, respectively, containing Polysorbate 20, to determine the extent of oxidative degradation of Polysorbate 20 in the aqueous formulation.
[0030] Embodiments of the present invention will now be described by way of example with reference to the accompanying drawings, which illustrate embodiments of the present disclosure without limiting the specific embodiments incorporated in and configured to form a part of this specification, and which, together with the general description and detailed description, serve to explain the principles of the present disclosure. [Brief description of the drawings]
[0031] [Figure 1A] Left: Two full scan total ion chromatogram (TIC) extractions of polysorbate 20 in aqueous solution obtained from an embodiment of a liquid chromatography mass spectrometry (LC-MS) based method of the invention, both at a mass to charge ratio m / z of about 227 amu (226.5-227.5 amu), the upper spectrum showing the addition of oxidation catalyst AAPH and the lower spectrum showing no oxidation catalyst AAPH; Right: Two full scan total ion chromatogram (TIC) extractions of polysorbate 20 in aqueous solution obtained from an embodiment of a liquid chromatography mass spectrometry (LC-MS) based method of the invention, both at a mass to charge ratio m / z of about 487 amu (486.5-487.5 amu), the upper spectrum showing the addition of oxidation catalyst AAPH and the lower spectrum showing no oxidation catalyst AAPH; [Figure 1B]Three ion chromatograms obtained from an embodiment of the liquid chromatography mass spectrometry (LC-MS) based method of the invention on an oxidatively stressed aqueous solution of polysorbate 20: a total ion chromatogram (TIC, top panel), an extracted ion chromatogram at a mass to charge ratio m / z of about 227 amu (from m / z 226.5 to m / z 227.5 amu) (middle panel), and an extracted ion chromatogram at a mass to charge ratio m / z of about 487 amu (from m / z 486.5 to m / z 487.5 amu) (bottom panel); [Figure 1C] High-resolution mass spectrum of the peak eluting at 18.4 minutes obtained from an embodiment of a liquid chromatography mass spectrometry (LC-MS) based method of the present invention as shown in the chromatograms in Figures 1A and 1B; [Figure 1D] Two mass spectra obtained from an embodiment of a liquid chromatography mass spectrometry (LC-MS) based method of the invention, one mass spectrum of commercially available polyethylene glycol-6-laurate (top panel) and one mass spectrum of polyethylene glycol-6-laurate from AAPH-stressed polysorbate 20 (bottom panel); [Figure 2A] Polysorbate 20 concentration [mg / mL] present in the aqueous formulation plotted against time [hr] (left y-axis) and the relative peak area of the oxidative marker polyethylene glycol-6-laurate plotted against time [hr] (right y-axis, also referred to as "Oxmarker"), as analyzed via HPLC-CAD, obtained from an embodiment of a liquid chromatography mass spectrometry (LC-MS) based method of the invention; [Figure 2B] FIG. 1 is a block diagram of intact polysorbate 20 species levels plotted versus time [hours] for aqueous formulations containing polysorbate 20 using an embodiment of a liquid chromatography mass spectrometry (LC-MS)-based method of the present invention; [Diagram 3]Chemical structures of some intact polysorbate 20 species present in polysorbate 20, namely POE-sorbitan mono C12, POE-isosorbide mono C12, POE mono C12 and POE-sorbitan di C12; [Figure 4A] Polysorbate 20 concentrations [mg / mL] present in aqueous formulations containing monoclonal antibodies in different variants plotted against time [months] as determined by HPLC-CAD analysis; [Figure 4B] Relative levels of polyethylene glycol-6-laurate (P6L) oxidation marker based on relative peak area [%] present in the aqueous formulation of FIG. 4A plotted against time [months] as determined by a liquid chromatography mass spectrometry (LC-MS) based method according to an embodiment of the present invention; [Figure 5A] 1 is a block diagram of intact polysorbate 20 species levels as relative peak area [%] over a 3-month period, illustrating a stability study of an aqueous placebo formulation (placebo vs. mAb-1 formulation) using an embodiment of a liquid chromatography mass spectrometry (LC-MS)-based method of the present invention; [Figure 5B] FIG. 1 is a block diagram of intact polysorbate 20 species levels as relative peak area [%] over a 3-month period, illustrating a stability study of a monoclonal antibody containing aqueous formulation (mAb-1 formulation; variant A) using an embodiment of a liquid chromatography mass spectrometry (LC-MS)-based method of the present invention; [Figure 6A] Polysorbate 20 concentrations [mg / mL] present in aqueous formulations containing monoclonal antibodies in different variants plotted against time [months] as determined by HPLC-CAD analysis; [Figure 6B] Relative levels of polyethylene glycol-6-laurate (P6L) oxidation marker based on relative peak area [%] present in the aqueous formulation of FIG. 6A plotted against time [months] as determined by a liquid chromatography mass spectrometry (LC-MS) based method according to an embodiment of the present invention; [Figure 7A]FIG. 1 is a block diagram of intact polysorbate 20 species levels as relative peak area [%] plotted against time [months] representing a stability study of a monoclonal antibody containing aqueous formulation (mAb-2 formulation; variant B) using an embodiment of a liquid chromatography mass spectrometry (LC-MS) based method of the present invention; [Figure 7B] FIG. 1 is a block diagram of intact polysorbate 20 species levels as relative peak area [%] plotted against time [months] representing a stability study of a monoclonal antibody containing aqueous formulation (mAb-2 formulation; variant A) using an embodiment of a liquid chromatography mass spectrometry (LC-MS) based method of the present invention; [Figure 8A] Polysorbate 20 concentration [mg / mL] present in aqueous formulations containing monoclonal antibody (mAB-4 formulation) and placebo for monoclonal antibody (placebo for mAB-4 formulation) plotted against time [months] as determined by HPLC-CAD analysis; [Figure 8B] Relative levels of polyethylene glycol-6-laurate (P6L) oxidation marker based on relative peak area [%] present in the aqueous formulation of FIG. 8A plotted against time [months] as determined by a liquid chromatography mass spectrometry (LC-MS) based method according to an embodiment of the present invention; [Figure 9] Standard curve for the liquid chromatography mass spectrometry (LC-MS) based method of the present invention, where the detection area (y-axis) of the liquid chromatography mass spectrometry (LC-MS) analysis (LC-MS P6L) is plotted against the concentration (x-axis) of standard solutions of polyethylene glycol-6-laurate (1-25 ng / mL). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0032] General definitions Terms not specifically defined herein should be given the meaning given to them by one of ordinary skill in the art in light of this disclosure and the context.
[0033] The term "polysorbate 20" or "PS20" stands for polyoxyethylene (20) sorbitan monolaurate, which is commercially available as a mixture of structurally related molecules containing predominantly sorbitan polyoxyethylene fatty acid esters with substantial amounts of polyoxyethylene, sorbitan polyoxyethylene, and isosorbide polyoxyethylene [1, 2, 4]. The molecular heterogeneity of polysorbates arises from variability within their three functional groups, i.e., polydispersity in terms of the length of the EO chains at the hydrophilic head, differences in the length of the chains (number of carbons), and the degree of fatty acid unsaturation at the hydrophobic tail, as well as the presence of species containing cores composed of sorbitol monoanhydrides and dianhydrides (sorbitan and isosorbide, respectively). Furthermore, depending on the number of fatty acid esters per structure, polysorbates may contain mono-, di-, tri-, and tetraesters. An overview of the composition of the various polysorbates is provided in Table 1 of [1].
[0034] According to the European Pharmacopoeia (Ph.Eur.) specifications, in terms of fatty acid content, lauric acid esters account for 40-60% of the esters in polysorbate 20, with the remaining esters being in the C8-C18 range. However, for simplicity, it is customary to consider PS20 as the polyethoxylated (POE) sorbitan monoester of lauric acid.[6] The theoretical structure of polysorbate 20, shown in Figure 1, is as follows:
[0035] [ka] It is believed that this is why the complex compositions of polysorbates represent excellent surfactants with many applications.
[0036] The term "oxidation marker" or "oxidative marker" (also abbreviated as oxmarker), as used herein, refers to a compound associated with, and in particular a compound formed during, the oxidative degradation of polysorbate 20. Thus, the presence of an oxidation marker at a level higher than that of its impurities means that oxidative degradation of polysorbate 20 is occurring or has occurred. The oxidation marker herein is polyethylene glycol-6-laurate. The expression "oxidative degradation" of polysorbate 20 refers to free radical initiated degradation, also known as autoxidation. Oxidative degradation is distinct from the hydrolysis of polysorbate 20, which is typically catalyzed by host cell impurities and results in the release of free fatty acids.
[0037] The term "degree of oxidative degradation", as used in the present invention, indicates the extent of oxidative degradation of polysorbate 20, in particular how far oxidative degradation has already progressed, so that it is possible to estimate how much or to what extent polysorbate 20 has already been oxidatively degraded. The degree of oxidative degradation is proportional to the relative or absolute amount or level of the oxidation marker polyethylene glycol-6-laurate in the aqueous formulation containing polysorbate 20. A relative amount or level in a sample means an amount or level relative to a reference sample or in another sample. An absolute amount or level is the actual amount analytically determined by quantitative analysis.
[0038] The term "proportional" in the expression "the relative peak area [of polyethylene glycol-6-laurate] is proportional to the extent of oxidative degradation of polysorbate 20," and similar phrases, should be understood to mean that there is a relationship or correlation between the relative peak area of the oxidation marker polyethylene glycol-6-laurate in a sample and the extent of oxidative degradation of polysorbate 20. In particular, a proportional relationship, or more precisely an inverse proportional relationship, exists, i.e., the amounts or levels (relative or absolute) of polyethylene glycol-6-laurate and the amounts or levels (relative or absolute) of polysorbate 20 are uncorrelated with each other, as will be explained in more detail below. The expression "level" should be understood in its broadest sense and means the amount, part, content or concentration of a compound present in an aqueous liquid, in particular a reference sample or aqueous formulation. "Relative level" means the amount, part, content or concentration of a compound expressed relative to or with respect to a reference.
[0039] The term "aqueous" is intended to mean that water is present in the formulation. For example, water may constitute part of the solvent, e.g., a part or a major part of the solvent, or it may represent the only solvent present. Indeed, any type of water may be used. Purified water may be preferred, but tap water may also be used according to some embodiments. The type of water selected depends on the intended use of the aqueous formulation. Purified water used according to the present invention is water that has been subjected to a purification process, e.g., distillation, reverse osmosis, carbon filtration, volumetric or electrodeionization, microfiltration or ultrafiltration, ultraviolet oxidation, etc., to remove impurities so that it is suitable for use. Combinations of these processes may also be used to achieve water of high purity, e.g., ultrapure water, whose trace contaminants are measured in parts per billion (ppb) or parts per trillion (ppt). The water used may also be ultrapure water, e.g., type 1 ultrapure water (Milli-Q® water), according to ASTM D1193 or ISO3696. The water used may also be sterile water, e.g., water for injection (WFI), suitable for administration to a subject. Also, distilled, double-distilled or deionized water can be used. The term "aqueous formulation" refers to a solution in which the solvent or one of the solvents is water. Solutions include true solutions, dispersions, suspensions, etc., unless otherwise stated. Aqueous formulations according to the present invention include polysorbate and any one or more proteins and optional excipients.
[0040] The term "protein" (used interchangeably with "polypeptide" and "amino acid residue sequence") refers to any polymer of amino acids (natural or artificial) of any length. The term "protein" also includes proteins that are post-translationally modified through reactions including, but not limited to, glycosylation, glycation, acetylation, phosphorylation, oxidation, amidation or protein processing. Modifications and changes, such as fusion to other proteins, amino acid sequence substitutions, deletions or insertions, can result in the structure of a polypeptide, preferably with the molecule maintaining its biological functional activity. For example, certain amino acid sequence substitutions can result in a polypeptide or its underlying nucleic acid coding sequence to obtain a protein with similar properties. Amino acid modifications can be prepared, for example, by performing site-directed mutagenesis or polymerase chain reaction-mediated mutagenesis in the underlying nucleic acid sequence. Thus, the term "protein" or "polypeptide" also includes, for example, fusion proteins consisting of an immunoglobulin component, such as an Fc component, and a growth factor, such as an interleukin.
[0041] The term "protein" includes proteins, polypeptides, fragments thereof, peptides, fusion proteins, all of which can be expressed in a host cell system or synthesized via chemical methods. The desired protein can be, for example, an antibody, an enzyme, a cytokine, a lymphokine, an adhesion molecule, a receptor and derivatives or fragments thereof, as well as any other protein or polypeptide that can function as an agonist or antagonist and / or have therapeutic or diagnostic use.
[0042] Further desired proteins or polypeptides are, for example, but not limited to: insulin, insulin-like growth factor, hGH, tPA, cytokines such as interleukins (IL), such as IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, interferon (IFN) alpha, IFN beta, IFN gamma, IFN omega or IFN tau, tumor necrosis factor (TNF), such as TNF alpha and TNF beta, TNF gamma, TRAIL; G-CSF, GM-CSF, M-CSF, MCP-1, VEGF and single domain antibodies (e.g. from Camelidae). Also included is the production of erythropoietin or any other hormone growth factor and any other polypeptide that can function as an agonist or antagonist and / or have therapeutic or diagnostic uses. Thus, the protein can be, for example, an antibody, such as a monoclonal antibody, a polyclonal antibody, a monospecific antibody, a multispecific antibody, a single chain antibody or an antibody fragment thereof, such as Fv, scFv, Fab, Fab', scFab, F(ab')2, Fab2, Fc and Fc' fragments, heavy and light immunoglobulin chains and their constant, variable or hypervariable regions and Fv and Fd fragments, a bispecific antibody, a trispecific antibody, a scFv-Fc, a minibody, or a single domain antibody, or a mixture thereof.
[0043] The term "antibody" as normally used herein refers to a monospecific antibody, but antibodies may also be multispecific or fragments thereof. Exemplary antibodies within the scope of the present invention include, but are not limited to, anti-CD2, anti-CD3, anti-CD20, anti-CD22, anti-CD30, anti-CD33, anti-CD37, anti-CD40, anti-CD44, anti-CD44v6, anti-CD49d, anti-CD52, anti-EGFR1 (HER1), anti-EGFR2 (HER2), anti-GD3, anti-IGF, anti-VEGF, anti-TNFalpha, anti-IL2, anti-IL-5R, anti-IL-36R or anti-IgE antibodies, preferably selected from the group consisting of anti-CD20, anti-CD33, anti-CD37, anti-CD40, anti-CD44, anti-CD52, anti-HER2 / neu (erbB2), anti-EGFR, anti-IGF, anti-VEGF, anti-TNFalpha, anti-IL2, anti-IL-36R and anti-IgE antibodies.
[0044] The term "antibody", "antibody" or "immunoglobulin" as used herein refers to a protein selected from globulins, which are formed naturally as a response of the host organism to foreign substances (=antigens) from differentiated B lymphocytes (plasma cells). There are various classes of immunoglobulins: IgA, IgD, IgE, IgG, IgM, IgY, IgW. The antibody may be an IgG antibody, such as an IgG1 antibody or an IgG4 antibody. The terms "immunoglobulin" and "antibody" are used interchangeably herein. Antibodies include monoclonal, monospecific and multispecific (e.g. bispecific or trispecific) antibodies, single chain antibodies, antigen-binding fragments of antibodies (e.g. Fab or F(ab')2 fragments), disulfide-linked Fvs, etc. Antibodies may be of any species and include chimeric and humanized antibodies.
[0045] The term "sample" is understood as broadly as possible to mean a limited or smaller amount of an aqueous preparation that is taken for analysis. Sampling can be performed manually or by automated methods. The term "liquid chromatography mass spectrometry" or "LC-MS method" refers to a method known in the prior art based on a specific analytical chemistry technique that combines physical separation by liquid chromatography (or HPLC) with mass analysis by mass spectrometry (MS). This expression is intended to include any technique combined with liquid chromatography and mass spectrometry known to the skilled artisan. Coupled liquid chromatography-MS systems are known in chemical analysis. They present the advantage of a synergistic improvement of the two methods, usually in combination. LC-MS systems also contain some kind of interface that allows the substances separated by the LC procedure to enter the MS ion source. The interface is necessary since LC and MS devices are practically compatible with each other. In LC systems, the mobile phase is under pressure, while the MS analyzer is usually under high vacuum.
[0046] The expression "liquid chromatography mass spectrometry based method" or "LC-MS based method" should be understood as a method used according to the present invention comprising liquid chromatography and mass spectrometry, which in turn is directly carried out, whereby a method known to the skilled person in the prior art ("LC-MS method" as defined above) serves as a basis, on which the method of the present invention is based, modified and adapted in the manner disclosed herein to meet the desired requirements, in particular to target and quantify oxidation markers.
[0047] The expressions "quantifying" or "quantification" and the like should be understood in their broadest sense and refer to determining the concentration or amount of the substance polyethylene glycol-6-laurate based on the relative levels (relative peak areas) found and present in the aqueous formulation being sampled and tested. Quantification is achieved by external calibration using standard solutions of polyethylene glycol-6-laurate. The term "recombinant protein" as used herein relates to a protein produced by recombinant techniques such as molecular cloning. Such methods combine genetic material from multiple sources or create sequences that do not occur in nature. Recombinant proteins are typically based on sequences from different cells or organisms, or from different species from the recipient host cells used to produce the protein, e.g. CHO cells or HEK293 cells, or are based on artificial sequences such as fusion proteins. In the context of the present invention, the recombinant protein is preferably a therapeutic protein, such as an antibody, an antibody fragment, a molecule derived from an antibody (e.g. scFv, bispecific or multispecific antibodies), or a fusion protein (e.g. Fc fusion protein).
[0048] The term "expressing a recombinant protein," as used herein, refers to cells that contain a DNA sequence encoding a recombinant protein, which is transcribed and translated into a protein sequence including post-translational modifications, i.e., resulting in the production of the recombinant protein in cell culture. The term "eukaryotic cell" as used herein refers to a cell that has a nucleus within a nuclear membrane and includes animal cells, human cells, plant cells and yeast cells. In the present invention, "eukaryotic cells" specifically encompass mammalian cells, such as cells derived from Chinese Hamster Ovary (CHO) cells or HEK293 cells, and yeast cells. The term "drug substance" as used herein refers to a formulated active pharmaceutical ingredient (API) with excipients. The API has a therapeutic effect in the body in contrast to the excipients, which aid in the delivery of the API. In the case of biological therapeutics, the formulated API with excipients typically refers to the API in the final formulation buffer at a concentration of at least the maximum concentration used in the final dosage form, also called the drug product.
[0049] An API may be present in the aqueous formulation. According to WHO guidelines, an "active pharmaceutical ingredient (API)" is any substance or combination of substances used in a finished pharmaceutical product (FPP) that is intended to have a pharmacological activity or to have a direct effect in the diagnosis, cure, mitigation, treatment or prevention of a disease, or to have a direct effect in the restoration, correction or modification of a physiological function in humans. Additionally, excipients may be present in the aqueous formulation. An API may be, for example, one or more proteins. An aqueous formulation containing an API is considered an aqueous biopharmaceutical formulation. The term "pharmaceutical product" as used herein refers to the final commercially available dosage form of a drug substance, e.g., a tablet or capsule, or, in the case of biologics, typically a solution for injection in suitable containment such as a vial or syringe. The pharmaceutical product may also be in lyophilized form. The term "host cell proteins" (HCPs) refers to process-related protein impurities produced by the host organism during the manufacturing and production of biopharmaceuticals. During the purification process, the majority of the HCPs produced, usually more than 99%, are removed from the final product. However, the remaining HCPs remain in the final drug product, and the removal of HCPs is one of the biggest challenges in the production of biopharmaceuticals. Therefore, all proteins present in the expression system or substrates close to the protein of interest are considered as impurities and are usually outlined under the term host cell proteins (HCPs).
[0050] The expressions "comprising," "including," "including," "containing," "containing" or "contained" also encompass the more specific term "consisting of," unless otherwise stated or clear from the context. Additionally, it should be noted that the present disclosure does not use the singular and plural in a restrictive manner, and thus, as used herein, the singular forms "a," "an," "one," and "the" refer to both the singular and the plural unless otherwise stated or clear from the context. The expression "about" or "approximately" means within 10%, particularly 5% or more, more particularly within 1% or within 0.1% of a specific value or upper or lower range value indicated. For mass-to-charge ratios, the term "about" has a mean ±0.5. This means that "about 227 amu" represents a range of 227-0.5 amu to 227+0.5 amu or 226.5 to 227.5 amu, and "about 487 amu" represents a range of 487-0.5 amu to 487+0.5 amu or 486.5 to 487.5 amu.
[0051] EMBODIMENTS OF THE PRESENT DISCLOSURE Subsequently, the multi-step method according to the present invention is described. The optimal process conditions and parameters for each individual step may vary depending on the specific aqueous formulation, any excipients, the selected non-aqueous solvent, and any API present. Unless otherwise specified, the process conditions and parameters for each process step can be easily selected by those skilled in the art. The experimental procedure is presented in the experimental section. Polyethylene glycol-6-laurate has been found to be a marker substance that provides an indication as to the degree of oxidative degradation of polysorbate 20. Since polyethylene glycol-6-laurate is identified as a novel marker substance that allows specific monitoring of the oxidative degradation of polysorbate 20, it is also referred to as an oxidative marker or oxidation marker of the degradation of polysorbate 20. By using a liquid chromatography mass spectrometry based method, adapted and modified accordingly to the present invention, the relative levels of the marker substances in the samples can be determined and therefore the oxidative degradation of polysorbate 20 can be inferred.
[0052] The general procedure for the liquid chromatography-mass spectrometry based method according to the present invention is as follows: First, a chromatographic method is carried out, which is a liquid chromatographic process, in particular an HPLC process. The chromatographic procedure is followed by mass spectrometry. In mass spectrometry, electrospray ionization (ESI) is usually used to generate the ions that are used to determine the molecular weight. In this method, the polysorbate species are (partially) fragmented in the ESI source to isolate fragments that contain, in particular, fatty acids. This means that 1,3-dioxolanylium ions are generated. In this way, all ions can be measured. Usually, all ions are measured with a mass-to-charge ratio (m / z) in the range of about 100 to about 2000. It makes it possible to extract the ion trajectories of the detected species for evaluation: these are the so-called extracted ion chromatograms or XICs (Extracted Ion Chromatograms).
[0053] Such an extracted ion chromatogram or XIC is generated, for example, for an ion trace representing the 1,3-dioxolanylium ion of lauric acid or a typical fragment of polysorbate 20 at a mass to charge ratio of about 227 amu (from m / z 226.5 to m / z 227.5 amu). However, in the present invention, it has been found to be advantageous, and will be explained in more detail later, if an extracted ion chromatogram XIC is generated for data evaluation with an ion trace or mass to charge ratio including about 487 amu, in particular in the range including or consisting of m / z 486.5 to m / z 487.5 amu.
[0054] The individual steps of the method according to the invention will now be explained in detail below: First method, 1. Alternative: In a first alternative of the first method for determining the extent of oxidative degradation of polysorbate 20 in an aqueous formulation containing polysorbate 20, a first sample of the aqueous formulation to be tested is taken as a reference sample.
[0055] - Process Step 1 Process step 1 involves providing a first sample of the aqueous formulation to be tested, which acts as a reference sample. Reference is necessary because the presence of the oxidation marker polyethylene glycol-6-laurate itself does not mean that oxidative degradation occurs, since the aqueous formulation under investigation may already contain the oxidation marker as an impurity. Oxidative degradation may also already take place in the aqueous formulation. When oxidative degradation of polysorbate 20 occurs, it is a continuous process that forms increasing amounts of polyethylene glycol-6-laurate. Oxidative degradation may be caused by various influences, especially environmental influences such as light, the presence of metal ions, etc. Thus, the first sample as a reference sample is used to determine the base value, and the polyethylene glycol-6-laurate in the sample is determined relative to the base value. In the present context, it should be noted that commercially available polysorbate 20 raw materials (solids) usually readily contain polyethylene glycol-6-laurate, as polyethylene glycol-6-laurate is also present in formulations containing aqueous polysorbate 20. If, contrary to expectations, the reference sample does not contain polyethylene glycol-6-laurate, a separate reference sample is provided.
[0056] - Process Step 2 In process step 2, a second sample and any further samples of the aqueous formulation to be tested are provided. It thus allows more than one sample of the aqueous formulation to be tested, for example 2, 3, 4, 5 or more further samples, to be taken in step 2. The number of samples will depend on the individual case. According to an embodiment, where the samples are taken in successive time intervals T1, T2, T3..., the times T1, T2, T3... may be of the same or different length. For example, the samples may be taken sequentially at time intervals, for example of the same length. For example, one sample may be taken over a period of several months, with a time interval of one month. In this way, it is possible to check whether or to what extent oxidative degradation of polysorbate 20 occurs over a certain period of time. The sampling in steps 1 and 2 can be carried out by any procedure known to the expert, for example manually by a human being or by an automated device or system. It goes without saying that the sampling should be carried out in such a way that the following analytical procedures are not adversely affected or impaired. The amount of sample taken from the aqueous formulation is selected to be large enough to carry out a liquid chromatography mass spectrometry based method on the sample. The skilled person is familiar with the fundamentals of this analytical technique.
[0057] - Process Step 3 In the subsequent process step 3, a liquid chromatography mass spectrometry based method is used to separate polyethylene glycol-6-laurate and determine the relative peak area of polyethylene glycol-6-laurate, a marker substance for the oxidative degradation of polysorbate 20, in the reference sample from step 1 and each sample of the aqueous formulation from step 2, respectively. Determination of the "relative peak area" or "relative level" of polyethylene glycol-6-laurate, terms used synonymously and interchangeably herein, means that in step 3, the polyethylene glycol-6-laurate level is determined relative to a reference sample. In particular, polyethylene glycol-6-laurate is separated from the reference sample (first sample) in step 1, from the second sample, and from any further samples in step 2, and in each case the peak areas of polyethylene glycol-6-laurate in the reference sample, the second sample, and each further sample are determined. The peak areas of polyethylene glycol-6-laurate in the second sample and each further sample are then determined relative to the peak area of polyethylene glycol-6-laurate in the reference sample to obtain relative peak areas for the second sample and each further sample.
[0058] The relative peak areas of polyethylene glycol-6-laurate for the second sample in process step 3 and for each of the further samples are compared to determine whether the peak areas are consistent with the following two possibilities: - calculating the resulting peak area difference, wherein the polyethylene glycol-6-laurate peak area of the reference sample is subtracted from the polyethylene glycol-6-laurate peak area of the second sample and from the polyethylene glycol-6-laurate peak area of each of the further samples, respectively, to obtain relative peak areas for the second sample and each of the further samples; or - normalizing the obtained peak areas, by setting the peak area of polyethylene glycol-6-laurate of the reference sample to 100% and calculating and normalizing the peak areas of polyethylene glycol-6-laurate of each of the second sample and any further samples, respectively, based thereon. The determination can be made by one of the following:
[0059] When the difference is formed, the peak area of the reference sample is subtracted from the peak area of each sample.The peak area of the reference is determined once properly, and then the obtained value (baseline) is subtracted from the obtained peak area of each sample, respectively.This is explained by using an example.
[0060] The following peak areas are determined by a liquid chromatography mass spectrometry based method: Peak area relative to reference sample: 2000. Peak area for the first sample: 3000. Relative peak area to the first sample: 3000-2000=1000. Peak area for further sample: 4000. Relative peak area for further sample: 4000-2000=2000. Negative values are not possible since the reference sample is the first sample taken from the aqueous formulation and therefore will usually have an equal or lesser content of polyethylene glycol-6 laurate than the other or any further samples taken. When the obtained peak areas are normalized, the peak area of polyethylene glycol-6-laurate of the reference sample is set to 100%, and the peak areas of polyethylene glycol-6-laurate of the second sample and each of any further samples are calculated based on this, respectively. This will be illustrated by another example.
[0061] The following peak areas are determined by a liquid chromatography mass spectrometry based method: Peak area relative to reference sample: 2000. Peak area for the other sample: 3000. The relative peak area to the reference sample is set to 100%. Relative peak area to second sample: ((3000×100):2000=) 150%. Peak area for further sample: 4000. The relative peak area to the reference sample remains set at 100%. Relative peak area to second sample: ((4000×100):2000=) 200%. Therefore, it is only necessary to determine the relative levels of polyethylene glycol-6-laurate in a sample of the aqueous formulation compared to a reference to determine whether oxidative degradation of polysorbate 20 occurs.
[0062] It goes without saying that when several samples are taken and analyzed, their polyethylene glycol-6-laurate levels are always determined as relative levels compared to a reference sample (relative peak areas). Thus, in step 3, one, two, three, four, five or more samples are each analyzed using a method based on liquid chromatography-mass spectrometry: for this purpose, the polyethylene glycol-6-laurate contained in the other sample is separated, its peak area is determined, and the relative peak area is determined relative to the peak area of the reference sample (first sample) using difference or normalization as already described to obtain the relative peak areas of the other samples. The same procedure is subsequently performed for each further sample, i.e., the polyethylene glycol-6-laurate contained in each further sample is respectively separated, its peak area is determined, and the relative peak area is determined relative to the peak area of the reference sample using difference or normalization as already described to obtain the relative peak areas of each further sample. This procedure is repeated for all samples, so that a series of relative peak areas can be determined. According to one embodiment, the relative peak areas can be determined as a function of sampling times T1, T2, . . .
[0063] It is useful if the calculation of the peak area relative to the reference sample is performed in the same way in all samples, i.e. if the difference is made for one sample, it is useful if the difference is used for all samples. If normalization is used for one sample, it is appropriate to use normalization for all samples. This ensures the comparability of the determination of the relative peak area of the samples.
[0064] The relative peak area for polyethylene glycol-6-laurate is proportional to the degree of oxidative degradation of polysorbate 20. That is, the degree of oxidative degradation is directly related to determining the relative level of the oxidation marker polyethylene glycol-6-laurate in the aqueous formulation being examined. To what extent polysorbate 20 is oxidatively degraded to form the oxidation marker polyethylene glycol-6-laurate. Therefore, based on the determined relative levels of the oxidation markers, the degree of oxidative degradation of polysorbate 20 estimates, in particular, how much oxidative degradation has already proceeded, and therefore how much or how much polysorbate 20 has already been oxidatively degraded. More precisely, there is an inverse proportional (non-correlated) relationship between the amount or level of polyethylene glycol-6-laurate and the amount or level of polysorbate 20, which will be explained in more detail later. Thus, the samples can be used to determine possible oxidative degradation pathways. For example, a significantly higher level of an oxidation marker present in a sample (e.g., a stability sample) relative to a corresponding reference sample indicates a higher degree of oxidative degradation of polysorbate 20.
[0065] However, in the present context, it must be taken into account that the proportionality is not obtained throughout the degradation process of polysorbate 20, since polyethylene glycol-6-laurate itself degrades over time. Thus, the skilled person will understand that the teachings of the present invention may be relevant to the extent that polyethylene glycol-6-laurate has not yet degraded and the described proportionality is obtained. Thus, the disclosed liquid chromatography mass spectrometry (LC-MS) based method serves as an analytical tool to determine the level of polyethylene glycol-6-laurate, which corresponds to a certain degree of oxidative degradation of polysorbate 20 in NBE (novel biological agent) solutions. Thus, the method of the present invention is also capable of distinguishing between oxidative and non-oxidative degradation of polysorbate 20, which can be explained in more detail below.
[0066] - Process Step 4 In process step 4, following step 3, polyethylene glycol-6-laurate may be quantified in the samples based on the relative peak areas of the second sample and each of any further samples. This step is merely optional, as it may be sufficient to determine whether oxidative degradation of polysorbate 20 has already occurred based on the relative levels of polyethylene glycol-6-laurate found. However, if a quantitative statement about the extent of oxidative degradation that has actually occurred is needed or desired, a quantitative analysis may be performed in either case. Quantification is carried out in particular via external calibration.For example, the quantification of step 4 can be carried out with external calibration using a standard solution of polyethylene glycol-6-laurate.This procedure is known to those skilled in the art, and therefore it is not necessary to describe the procedure in detail in full. Quantification of polyethylene glycol-6-laurate can be very useful, for example, when the absolute values obtained by the quantification are used in an array of established limits and / or ranges.
[0067] - Process Step 5 Process step 5 involves estimating how much polysorbate 20 has already been oxidatively degraded in the sample based on the (approximately) inverse relationship between the polyethylene glycol-6-laurate level and the level of polysorbate 20. The extent of oxidative degradation of polysorbate 20 in the sample can be estimated based on the relative peak area of polyethylene glycol-6-laurate determined in step 3, or the amount of polyethylene glycol-6-laurate determined in step 4 based on the relative peak area of polyethylene glycol-6-laurate.
[0068] Thus, not only is it possible to distinguish between non-oxidative and oxidative degradation of polysorbate 20 in an aqueous formulation, but the pathway and progression of oxidative degradation can be determined using the method of the present invention. The (approximately) inverse proportional relationship is indicated by the fact that when the (relative) polysorbate 20 level or content of a sample aqueous formulation is determined over time and the (relative) polyethylene glycol 6-laurate level or content of a sample aqueous formulation is determined over time, the determined values are plotted as two curves and compared to each other, and the two curves are (approximately) inversely proportional. Otherwise, although the curves are not inversely proportional to each other, oxidative degradation of polysorbate 20 does not occur.
[0069] As shown in Figure 2A, which will be described in detail later, there is a correlation between the drop in polysorbate 20 concentration due to oxidative degradation and the increase in the relative level of polyethylene glycol-6-laurate formed during oxidative degradation. To an approximation, it can be assumed that the concentration of polysorbate 20 is inversely proportional to the relative level of polyethylene glycol-6-laurate. This shows that oxidative degradation of polysorbate 20 occurs in Figure 2A. This allows for an estimation of the oxidative degradation of polysorbate 20 based on the relative level of polyethylene glycol-6-laurate found in method step 3. Thus, a high value for the relative level of polyethylene glycol-6-laurate indicates high degradation of polysorbate 20 in the sample investigated, a median value for the relative level of polyethylene glycol-6-laurate indicates moderate degradation of polysorbate 20 in the sample tested, and a low value for the relative level of polyethylene glycol-6-laurate indicates low degradation of polysorbate 20 in the sample tested.
[0070] If the estimation of oxidative degradation based on the determined relative polyethylene glycol-6-laurate levels is correlated with time, it provides very useful information about the oxidative degradation behavior of polysorbate 20 in aqueous formulations. This is of particular interest in stability studies of aqueous formulations, e.g. during development, manufacture, shelf-life or storage thereof, or for aqueous biopharmaceutical formulations, e.g. to check their quality over time. It is then also possible to estimate how much oxidative degradation of polysorbate 20 is most likely to develop over time in aqueous formulations containing polysorbate 20, particularly aqueous biopharmaceutical formulations, or what level of oxidative degradation of polysorbate 20 can be predicted at a certain time point. This can be derived by estimating the level of oxidative degradation of polysorbate 20 in aqueous formulations, e.g. biopharmaceutical formulations, carried out using the method of the present invention. Identical or very similar biopharmaceutical formulations behave in the same or correspondingly similar manner. Thus, estimations are possible and are particularly useful for the development of aqueous formulations, particularly aqueous biopharmaceutical formulations. 1st method, 2nd alternative: In an alternative embodiment of the first method (alternative 2.) for determining the extent of oxidative degradation of polysorbate 20 in aqueous formulations containing polysorbate 20, an external reference sample is used. Except for this difference, all of the descriptions for the first alternative apply to the same method for the second alternative.
[0071] - Process Step 1' In process step 1', a reference sample is provided which is an aqueous solution containing polysorbate 20 and has the same polysorbate content as the aqueous formulation to be tested. For example, commercially available polysorbate 20 can be used. Since polysorbate 20 usually already contains polyethylene glycol-6-laurate, aqueous solutions of polysorbate 20 also contain it. In process step 1', an external reference sample used to determine the base value is provided and the polyethylene glycol-6-laurate in the sample is determined relative to the base value. In other words, the explanation for the reference sample in step 1 applies mutatis mutandis herein.
[0072] - Process Step 2' In process step 2' a first sample of the aqueous formulation to be tested and any further samples are provided. Thus allowing more than one sample of the aqueous formulation to be tested to be taken in step 2', for example 2, 3, 4, 5 or more further samples. The number of samples depends on the individual case. According to one embodiment, samples are taken in sequential successive time intervals T1, T2, T3..., which may be of equal or different duration. The sampling in steps 1' and 2' can be carried out by any procedure known to the expert, for example manually by a human being or by an automated device or system. It goes without saying that the sampling should be carried out in such a way that the following analytical procedures are not adversely affected or impaired. The amount of sample taken from the aqueous formulation is selected so that it is large enough to carry out a liquid chromatography mass spectrometry based method on the sample. The skilled person is familiar with the fundamentals of this analytical technique.
[0073] - Process Step 3' In process step 3' below, a liquid chromatography mass spectrometry based method is used to separate the polyethylene glycol-6-laurate and determine the relative peak areas of polyethylene glycol-6-laurate in each sample, thereby using an external reference in place of the first sample.
[0074] In particular, the liquid chromatography mass spectrometry based method of the present invention is used to separate polyethylene glycol-6-laurate from the reference sample in step 1' and from the first sample and any further samples in step 2', and in each case determine the peak areas of polyethylene glycol-6-laurate in the reference sample, the first sample and any further samples. The peak areas of polyethylene glycol-6-laurate in the first sample and any further samples are then determined relative to the peak area of polyethylene glycol-6-laurate in the reference sample to obtain relative peak areas for the first sample and any further samples. Rather than determining the peak area of polyethylene glycol-6-laurate in the reference sample for each sample, it is convenient to determine the peak area once and use this value (baseline) as a reference.Then, for each sample taken, its peak area is determined relative to this value (baseline) of the peak area of the reference.
[0075] The relative peak areas in process step 3' have two possibilities: - calculating the resulting peak area difference, wherein the polyethylene glycol-6-laurate peak area of the reference sample is subtracted from the polyethylene glycol-6-laurate peak area of the first sample and from the polyethylene glycol-6-laurate peak area of each of any further samples, respectively, to obtain relative peak areas for the first sample and each of any further samples; or - normalizing the obtained peak areas, by setting the peak area of polyethylene glycol-6-laurate of the reference sample to 100% and calculating and normalizing the peak areas of polyethylene glycol-6-laurate of the first sample and each of any further samples, respectively, based thereon. The determination can be made by one of the following: Additionally, the further explanation of step 3 also applies herein.
[0076] - Process steps 4' and 5' In process step 4', the compound polyethylene glycol-6-laurate may be quantified, so that the relative peak areas of the first sample and each of any further samples are taken as a basis. In process step 5', it is possible to estimate how much polysorbate 20 has already been oxidatively degraded in the sample based on the inverse relationship between polyethylene glycol-6-laurate levels and polysorbate 20 levels. The descriptions for process steps 4 and 5 apply herein in a corresponding manner to process steps 4' and 5'. Second method: The present invention also provides a (second) method for determining the degree of oxidative degradation of polysorbate 20 in several aqueous formulations, in particular each aqueous formulation containing the same amount of polysorbate 20. The number of aqueous formulations is not limited, for example 2, 3, 4, 5 or more aqueous formulations can be used, in particular up to 10, up to 20, up to 50 or even more aqueous formulations can be used. The aqueous formulations can differ from each other in terms of their composition, but are in particular selected to be the same only in terms of their polysorbate 20 content.
[0077] - Process Step 1a In process step 1a, a sample of each aqueous formulation to be tested, each containing polysorbate 20, is provided. Sampling can be performed by any procedure known to the expert, for example manually by a human being or by an automated device or system. It goes without saying that sampling should be performed in such a way that the following analytical procedures are not adversely affected or impaired. The amount of sample taken from the aqueous formulation is selected to be large enough to carry out a liquid chromatography-mass spectrometry based method on the sample. The skilled person is familiar with the fundamentals of this analytical technique. The peak areas of samples in this second method can be compared with each other, so there is no need to use a reference herein. This is particularly useful when performing sequential testing. For example, different formulation compositions can be tested for their stability. According to one embodiment, it is also possible to select a reference sample from the collected samples and determine the relative peak areas of each sample with respect to this reference sample. Which sample is selected as the reference sample may vary from case to case.
[0078] - Process Step 2a In process step 2a, a liquid chromatography and mass spectrometry based method is used to separate polyethylene glycol-6-laurate from each sample of step 1a and determine the peak area of polyethylene glycol-6-laurate in each sample, polyethylene glycol-6-laurate being a marker substance for the oxidative degradation of polysorbate 20. The peak areas of the samples are then compared to each other, such that the change in the peak area of the samples is proportional to the extent of oxidative degradation of polysorbate 20. The relative peak areas of polyethylene glycol-6-laurate need not be determined here since samples can be indirectly compared to one another. However, in another embodiment, the relative peak area of each sample can be determined with respect to a reference sample, where the reference sample is one of the samples. Accordingly, the explanations for the first and second methods also apply herein.
[0079] - Process Step 3a In process step 3a, any quantification of the compound polyethylene glycol-6-laurate is carried out based on the peak area obtained for the respective sample. For this purpose, an external calibration curve is provided using standard solutions of polyethylene glycol-6-laurate. Such a procedure has already been described in connection with process steps 4 and 4'.
[0080] - Process Step 4a Step 3a is followed by process step 4a, which allows for an estimation of how much polysorbate 20 has already been oxidatively degraded in the sample based on the inverse relationship between polyethylene glycol-6-laurate levels and polysorbate 20 levels, as detailed herein. Therefore, as several aqueous formulations are tested for this purpose, a second method can also be used to determine the extent of oxidative degradation of polysorbate 20, distinguish between non-oxidative and oxidative degradation, and determine the pathway of oxidative degradation over time. The second method can be used, for example, for quality control, thus making it possible, for example, to identify a particularly stable composition from several different aqueous formulations. Next, some aspects of the present invention will be described in detail.
[0081] Polyethylene glycol-6-laurate (PEG-6-laurate) as a marker for specific oxidation of polysorbate 20 Indeed, polyethylene glycol-6-laurate is a commonly used and well-characterized substance, extensively described in the scientific literature and in various patent applications for its use, for example, as a detergent or as an educt for various esterified compounds [7], and is also known as an additive in cosmetic compositions, for example in hair conditioner / shampoo compositions [8, 9]. 24 H 48 O 8 The molecular structure of ) is as follows:
[0082] [ka] However, to date, polyethylene glycol-6-laurate has not been implicated in functioning as an oxidative marker in the assays described herein for degradation of polysorbate 20. Because polyethylene glycol-6-laurate is a well-characterized and known compound, one of skill in the art can readily detect and identify it using the liquid chromatography mass spectrometry (LC-MS) based methods disclosed herein.
[0083] The mixture of chemical compounds separated here by liquid chromatography are the various degradation products of polysorbate 20, which, as already explained, is itself already a mixture of different substances. The oxidation marker polyethylene glycol-6-laurate is now separated from this mixture so that its presence can be detected. For this purpose, a method based on liquid chromatography-mass spectrometry (LC-MS) is modified and adapted, inter alia, as follows: Liquid chromatography is used inter alia as preparative chromatography, especially in the form of column chromatography, in which a mixture of chemical compounds is separated using a column containing a solid stationary phase that is eluted with one or more mobile phases.
[0084] According to the present invention, in one embodiment, reversed phase chromatography is used in liquid chromatography. In contrast to normal phase chromatography, reversed phase chromatography uses a stationary phase with non-polar surface properties and a mobile phase with polar properties. Known polar solvents for reversed phase chromatography are, for example, water, methanol, and acetonitrile. Other solvents are also possible. According to one embodiment of the method based on liquid chromatography-mass spectrometry with liquid chromatography, gradient elution is used. For example, two mobile phases containing polar solvents are used. For example, water can be used as mobile phase A and acetonitrile, which may advantageously contain formic acid, for example 1% formic acid, can be used as mobile phase B. The gradient can start with a few percent of one of the mobile phases, in particular mobile phase B, for example 1-10%, in particular 1-5% of mobile phase B, and ends with 100% of mobile phase B. Mobile phase A then represents the remaining percentage of 100%. A linear ramp of the gradient can be used. The skilled person can easily find a suitable composition of the mobile phase or phases and a suitable gradient that can be used.
[0085] It is advantageous if a polar solvent is added to the sample containing the polysorbate 20 to be tested before carrying out the liquid chromatography. Polar solvents are in particular solvents used in liquid chromatography. In one embodiment of the present invention, the liquid chromatography as part of the liquid chromatography mass spectrometry based method is high performance liquid chromatography (HPLC), and ultra-high performance liquid chromatography can be used. UPLC is more effective compared to HPLC because it uses higher pump pressures. The pump pressure for HPLC is usually 40 MPa, and for UPLC it is around 100 MPa. UPLC uses a stationary phase with a smaller particle size compared to HPLC, so UPLC allows for the separation of smaller particles. According to one embodiment, the liquid chromatography is carried out by high performance liquid chromatography using reversed phase chromatography, whereby the separation of the different polysorbate species present in polysorbate 20 is carried out on the basis of their high hydrophobicity, so that polyethylene glycol-6-laurate can be separated by liquid chromatography using its hydrophobicity. The procedure itself is well known to the expert. The modified and adapted features of the liquid chromatography mass spectrometry based method are disclosed herein, and the skilled person can easily use known liquid chromatography mass spectrometry procedures to modify and adapt the present procedure according to the present disclosure for separating polyethylene glycol-6-laurate. Therefore, it is not necessary to describe the procedure in full detail. Thus, the skilled person can easily carry out and optimize the liquid chromatography as part of a liquid chromatography mass spectrometry (LC-MS) based method based on the details disclosed and the explanations given.
[0086] After liquid chromatography is performed, the separated polyethylene glycol-6-laurate can then be identified by liquid chromatography coupled with mass spectrometry. In one embodiment, mass spectrometry is performed with a heated electrospray ionization (HESI) source. In a further embodiment, the mass spectrometry is selected to be high resolution mass spectrometry (HR-MS), for example, high resolution mass spectrometry is used specifically for structural elucidation. According to another embodiment, for data evaluation of the liquid chromatography mass spectrometry based method of the present invention, an extracted ion chromatogram is generated from a mass charge ratio range including or consisting of about 487 amu, in particular 486.5 to 487.5 amu. Polyethylene glycol-6-laurate surprisingly exhibits a distinct m / z ratio in the mass spectrum that allows highly specific monitoring by liquid chromatography mass spectrometry based analysis. This allows for unambiguous identification of polyethylene glycol-6-laurate, when present.
[0087] Those skilled in the art can easily carry out the mass spectrometry based on the details disclosed and the explanations provided. To demonstrate why a mass to charge ratio m / z of about 487 amu, and in particular a mass to charge ratio m / z comprising or consisting of 486.5 to 487.5 amu, is particularly advantageous and especially suitable for detecting polyethylene glycol-6-laurate, reference is made to the spectra shown in Figures 1A-1D, which serve to show the autoxidation of polysorbate 20 and illustrate how polyethylene glycol-6-laurate can be determined, and in particular identified, by separation and detection in a sample using the liquid chromatography mass spectrometry (LC-MS) based method of the invention.
[0088] Samples consisting of polysorbate 20 in aqueous solution are prepared and an oxidation catalyst is added to the sample in the form of 2,2'-azobis-2-methyl-propanimidamide, dihydrochloride (also referred to in the art as 2,2-azobis(2-methylpropionamidine) dihydrochloride or 2,2'-azobis(2-amidinopropane) dihydrochloride) (AAPH) to induce oxidative degradation of polysorbate 20, i.e. artificially induce autoxidation of polysorbate 20. In particular, oxidative stress is applied to the aqueous polysorbate 20 solution using 1.5 mM 2,2'-azobis-2-methyl-propanimidamide, dihydrochloride (AAPH). Details of the sample preparation are described in the experimental section, chapter "1.1 Materials", point "c) Preparation of artificially stressed polysorbate 20 samples".
[0089] The oxidation catalyst AAPH is a water-soluble azo compound known as a model oxidant and free radical generator. As previously described, polysorbate 20 has a tendency to generate peroxides in situ as a result of autoxidation. Therefore, AAPH is used to stimulate the autoxidation of polysorbate 20. Additionally, another sample is prepared consisting of polysorbate 20 in an aqueous solution. No oxidation catalyst is added to the other sample.
[0090] Using the liquid chromatography mass spectrometry based method of the invention, the samples are investigated, one sample with the oxidation catalyst present and one sample without the oxidation catalyst. The mass spectrometry used as part of the liquid chromatography mass spectrometry based method is used in full scan mode and the spectra obtained are compared. Details of the liquid chromatography mass spectrometry based method used are described in the experimental section, chapter "1.2 Methods", point "c) Quantification of the oxidation marker PEG-6 laurate (P6L) via liquid chromatography mass spectrometry (LCMS P6L), however, the final step in the described procedure, i.e. quantification of polyethylene glycol-6-laurate, is not performed. The results are shown in Figures 1A-1D.
[0091] In Figure 1A, on the left, two full scan total ion chromatogram (TIC) extractions of polysorbate 20 in aqueous solution obtained from an embodiment of a liquid chromatography mass spectrometry (LC-MS) based method of the invention are shown at a mass to charge ratio m / z of about 227 amu (226.5 to 227.5 amu). The m / z ratio of about 227 amu is used to correspond to the laurate-esterified compounds known to be most prominent in polysorbate 20, namely the 1,3-dioxolanylium ion of lauric acid in particular. In Figure 1A, on the left, the top panel shows a stressed sample of polysorbate 20 solution, i.e., polysorbate 20 in aqueous solution, with the addition of the oxidation catalyst AAPH to artificially initiate oxidative degradation of polysorbate 20. The bottom panel on the left of Figure 1A shows an unstressed sample of polysorbate 20 solution, without the addition of the oxidation catalyst AAPH, i.e., polysorbate 20 in aqueous solution. The table shown on the left side of FIG. 1A summarizes the peaks seen as well as the peak areas for the spectra shown on the left across the top panel with the oxidation catalyst AAPH (referred to as "1.5 mM AAPH" in FIG. 1A) and without the oxidation catalyst AAPH (referred to as "No AAPH" in FIG. 1A).
[0092] Comparing the unstressed sample (Figure 1A, left, bottom panel) to the AAPH-stressed sample (Figure 1A, left, top panel), an approximately 3.4-fold increase in a structure eluting at a retention time of approximately 18.4 min, namely polyethylene glycol-6-laurate, is observed in the stressed sample. In Figure 1A, on the right side, two full scan total ion chromatograms (TICs) of polysorbate 20 in aqueous solution are shown extracted from an embodiment of the liquid chromatography mass spectrometry (LC-MS) based method of the present invention, both at a mass to charge ratio m / z of about 487 amu (486.5-487.5 amu), with the upper chromatogram showing the addition of oxidation catalyst AAPH and the lower chromatogram showing the absence of oxidation catalyst AAPH. However, both chromatograms in Figure 1A are shown at a mass to charge ratio m / z of about 487 amu (486.5-487.5 amu) on the right side. In these chromatograms, it can be seen that the peak at about 18.4 minutes is surprisingly 20 times higher (Figure 1A, right side) than the peak at about 18.4 minutes in the chromatogram at a mass to charge ratio m / z of about 227 amu (Figure 1A, left side). As a result, it can be concluded that the chromatogram is highly selective, has low interference, and is highly sensitive at an m / z ratio containing or consisting of about 487 amu, with the signal increasing by about 20-fold after AAPH stress at a retention time of about 18.4 min.
[0093] To illustrate the differences between the chromatograms based on data evaluation, reference is made to FIG. 1B, which shows ion chromatograms obtained from an embodiment of the liquid chromatography mass spectrometry (LC-MS)-based method of the present invention on an oxidatively stressed aqueous solution of polysorbate 20, namely, a total ion chromatogram (TIC; top chromatogram), an extracted ion chromatogram generated at a mass-to-charge ratio m / z of about 227 amu (from m / z 226.5× to m / z 227.5 amu; middle chromatogram), and an extracted ion chromatogram generated at a mass-to-charge ratio m / z of about 487 amu (from m / z 486.5× to m / z 487.5 amu; bottom chromatogram). In the top chromatogram, some peaks overlap. In the middle extracted ion chromatogram generated at an m / z ratio of about 227 amu (226.5-227.5 amu), there is interference from two peaks likely at a retention time of about 18.4 minutes, while the peak of the oxidation marker polyethylene glycol-6-laurate (referred to as "PEG-6-laurate") is included. In the lower extracted ion chromatogram generated at an m / z ratio including about 487 amu (486.5-487.5 amu), there is a single peak of the oxidation marker polyethylene glycol-6-laurate with superior selectivity and sensitivity since the mass spectrum is at an m / z ratio including about 487 amu. Thus, the m / z ratio including or consisting of about 487 amu shows superior selectivity and sensitivity compared to the m / z including or consisting of about 227 amu. It can therefore be seen that an m / z ratio comprising or consisting of about 227 amu with source fragmentation of free fatty acids is significantly less suitable than an m / z ratio comprising or consisting of about 487 amu without source fragmentation.Accordingly, data evaluation of a liquid chromatography mass spectrometry (LC-MS) based method using a mass-to-charge ratio m / z comprising or consisting of about 487 amu is particularly advantageous and is particularly suitable for detecting polyethylene glycol-6-laurate in a liquid chromatography mass spectrometry (LC-MS) based method.
[0094] In this regard, it should be noted that the value for the mass-to-charge ratio of 487 amu rather represents a value of about 487 amu. Thus, according to the invention, the mass-to-charge ratio is in particular in the range of 486.5 to 487.5 amu, which corresponds to about 487 amu.
[0095] To demonstrate that the structure underlying the peak eluting at approximately 18.4 min was previously identified and indeed represents polyethylene glycol-6-laurate, a liquid chromatography-mass spectrometry-based method using high resolution mass spectrometry is carried out. Details of the liquid chromatography-mass spectrometry-based method using high resolution mass spectrometry are described in the experimental section, chapter "1.2 Methods", point "b) High Resolution Mass Spectrometry (HR-MS)".
[0096] The deconvoluted mass spectrum is shown in FIG. 1C and shows a series of structures with about 443 Da, about 487 Da and about 531 Da. These structures could be identified through precise determination of the monoisotopic peaks as sodium adducts of laurate-esterified POE (polyoxyethylene) chain fragments containing 5, 6 and 7 oxy-ethylene units, respectively. The corresponding molecular structures are as follows: Peak at approximately 443 Da: C 22 H 44 O 7 (PEG-5-laurate) sodium adduct, Peak at approximately 487 Da: C 24 H 48 O 8 (PEG-6-laurate) sodium adduct, and Peak at approximately 531 Da: C 26 H 52 O 9 Sodium adduct of (PEG-7-laurate).
[0097] Polyethylene glycol-6-laurate (also referred to herein as PEG-6-laurate or P6L) shows the highest signal intensity at approximately 487 Da. It is particularly important that these three structures identified herein correspond to concepts in the art that suggest reduction of POE chains as a potential oxidation mechanism [1, 2]. Thus, these structures provide evidence that oxidation of polysorbate 20 occurs via this pathway.
[0098] To provide unambiguous identification and structure of polyethylene glycol-6-laurate by an orthogonal approach (verification of the chemical structure of polyethylene glycol-6-laurate by synthesis and reanalysis), commercially available polyethylene glycol-6-laurate synthesized by ChiroBlock GmbH, Bitterfeld-Wolfen, Germany was purchased, analyzed by the liquid chromatography mass spectrometry-based method of the present invention, and directly compared to a sample of stressed polysorbate 20 solution (polysorbate 20 in aqueous solution with added AAPH). Figure ID shows the upper mass spectrum (upper panel) and lower mass spectrum of commercially available polyethylene glycol-6-laurate from an embodiment of the liquid chromatography mass spectrometry (LC-MS)-based method of the present invention, as well as a sample of polyethylene glycol-6-laurate from polysorbate 20 stressed with AAPH (lower panel). As can be seen from FIG. 1D, the polyethylene glycol-6-laurate in the upper and lower spectra at 487.32497 Da and 487.32493 Da, respectively, are in very good agreement with the experimentally determined values, indicating that the commercial polyethylene glycol-6-laurate corresponds to the experimentally determined oxidation marker polyethylene glycol-6-laurate, confirming the identification of the oxidation marker structure of polyethylene glycol-6-laurate. The different values in the last decimal place are due to measurement errors, but are within the variability of the measurement.
[0099] Correlation between degradation of polysorbate 20 and polyethylene glycol-6-laurate concentration It is hoped that a decrease in the content of polysorbate 20 will be accompanied by an increase in the content of polyethylene glycol-6-laurate, since the oxidation markers of polysorbate 20 are increasingly formed as the oxidative degradation of polysorbate 20 progresses. Indeed, it can be seen that there is a direct correlation between the oxidative degradation of polysorbate 20 and the detection of the relative levels of the oxidation marker substances, as will be explained below. To investigate the correlation between relative polyethylene glycol-6-laurate levels and artificially induced degradation of polysorbate 20, polysorbate 20 samples are artificially degraded by adding 2,2'-azobis-2-methyl-propanimidamide, dihydrochloride (AAPH) at a suitable temperature selected to stimulate autoxidation of polysorbate 20. For sample preparation, refer to the Experimental section, chapter "1.1 Materials", point "c) Sample preparation of artificially stressed polysorbate 20".
[0100] Samples are taken at different time points to assess the progression of oxidative degradation of polysorbate 20. The progression of oxidative degradation of polysorbate 20 is also referred to herein as a stress period. In particular, polysorbate 20 concentration, relative levels of polyethylene glycol-6-laurate and relative levels of native polysorbate 20 species of artificially oxidized polysorbate 20 are determined at different sampling points. Polysorbate 20 concentration is analyzed in the samples via HPLC-CAD, and the levels of the oxidation marker polyethylene glycol-6-laurate as well as native polysorbate 20 species present in the samples are assessed via an embodiment of the liquid chromatography mass spectrometry (LC-MS) based method of the present invention. For a detailed description of the analysis of polysorbate 20 concentrations performed by HPLC-CAD, please refer to the experimental section, chapter "1.2 Methods", point "d) Quantification of polysorbate 20 via high performance liquid chromatography charged aerosol detection (HPLC-CAD)".
[0101] For a detailed description of the analysis of relative levels of the oxidation marker polyethylene glycol-6-laurate via an embodiment of a liquid chromatography-mass spectrometry (LC-MS) based method of the present invention, please refer to the experimental section, chapter "1.2 Methods", point "c) Quantification of the oxidation marker PEG-6 laurate (P6L) via liquid chromatography-mass spectrometry (LCMS P6L)". For a detailed description of the analysis of the relative levels of intact polysorbate 20 species present in a sample via an embodiment of a liquid chromatography mass spectrometry (LC-MS) based method of the present invention, please refer to the experimental section, chapter "1.2 Methods", point "a) Screening of intact polysorbate 20 species via liquid chromatography mass spectrometry (LC-MS POE)".
[0102] The results of the analysis are shown in Figure 2A, where the relative peak areas of polysorbate 20 concentration [mg / mL] (left y-axis) and the oxidative marker (referred to as "Oxmarker") polyethylene glycol-6-laurate (right y-axis) are plotted versus time [hours]. Polysorbate 20 concentrations as measured by HPLC-CAD are shown in the curve with triangles, while the relative levels of the oxidative marker polyethylene glycol-6-laurate as measured by an embodiment of the liquid chromatography mass spectrometry (LC-MS) based method of the invention are shown in the curve with circles.
[0103] In FIG. 2A, the polysorbate 20 concentration, represented by the curve with triangles, shows a continuous decrease from 0.043 mg / mL (0 h) to 0.009 mg / mL (35 h), which corresponds to the sampling time T 0 (0 hours) to sampling time T 6This corresponds to a loss of 79% polysorbate 20 concentration over the course of polysorbate 20 degradation (35 hours). This means that a continuous drop in polysorbate 20 concentration was observed throughout the progression of polysorbate 20 degradation. In addition, the HPLC-CAD method was validated as a stability-indicating HPLC method (data not shown), finding that the degradation of polysorbate 20 using AAPH is reliably and accurately reproduced and demonstrated. As a result, the measured curve (with triangles) representing the progression of polysorbate 20 degradation is reliably and precisely valued.
[0104] Additionally, the relative levels of the oxidation marker polyethylene glycol-6-laurate were assessed via a liquid chromatography mass spectrometry (LC-MS) based method embodiment of the present invention. The liquid chromatography mass spectrometry (LC-MS) analysis data is also shown in FIG. 2A. The reference sample was 0.01 mg / kg / day at time T 0 The relative peak area of polyethylene glycol-6-laurate, represented by the curve with circles, coincides with and correlates with the detected degradation of polysorbate 20, with a maximum at the sampling time T 4 (12 hours) (see FIG. 2A) and then decreases slightly. After 12 hours, the relative levels of polyethylene glycol-6-laurate decrease but remain higher than the initial levels. The relative levels of polyethylene glycol-6-laurate then decrease slightly again after 24 hours, consistent with more advanced degradation of polysorbate 20 by this time point. In this regard, it should be noted that polyethylene glycol-6-laurate is merely an intermediate product of the oxidative degradation of polysorbate 20, which is further degraded, resulting in the observed decrease in polyethylene glycol-6-laurate levels after 24 hours. Thus, it is indeed shown that the decrease in polysorbate 20 concentration correlates with the increase in the relative levels of polyethylene glycol-6-laurate.
[0105] This means that, to the extent that one skilled in the art can readily determine, there is a clear non-correlation between polyethylene glycol-6-laurate and polysorbate 20, demonstrating the suitability of polyethylene glycol-6-laurate as a direct marker for the artificial oxidative degradation of polysorbate 20. As already mentioned, polysorbate 20 is not a single substance, but represents a mixture of a series of different substances and species. The autoxidation of polysorbate 20 affects all compounds and species present in polysorbate 20. Therefore, it was checked whether the artificially induced autoxidation and degradation of polysorbate 20 actually occurs and covers other compounds as well. Thus, the relative levels of some intact polysorbate 20 species present in the polysorbate 20 starting material, i.e. the polyoxyethylene esters present in polysorbate 20, can be determined by an embodiment of the liquid chromatography-mass spectrometry-based method of the present invention, before the degradation of polysorbate 20 (see time T 0 = 0 h) and during the degradation of polysorbate 20. The results are shown in the block diagram of Figure 2B, where the relative peak areas found for the native polysorbate 20 species are plotted against time [h]. The native polysorbate 20 species analyzed are POE-sorbitan mono C12, POE-isosorbide mono C12, POE mono C12 and POE-sorbitan di C12, whose chemical structures are shown in Figure 3 (see
[10] ).
[0106] 2B shows a successive decrease in the relative levels (relative peak areas) for the species POE-sorbitan monoC12, POE-isosorbide monoC12, and POE-sorbitan diC12, all of which decrease with increasing duration of oxidative stress. The largest decrease is observed for POE-sorbitan diC12, a species found to be susceptible to oxidative degradation in polysorbate 20 during the experiment (data not shown). In other words, the degradation of polysorbate 20 in solution is confirmed by the relative levels of intact polysorbate 20 species found in an embodiment of a liquid chromatography mass spectrometry (LC-MS) based method as shown in FIG. 2B. Thus, there is a clear non-correlation between polyethylene glycol-6-laurate levels and intact polysorbate 20 levels, demonstrating the suitability of polyethylene glycol-6-laurate as a direct marker for the artificial oxidative degradation of polysorbate 20.
[0107] An aqueous formulation containing excipients and any other ingredients We find that polyethylene glycol-6-laurate functions as an authentic oxidation marker for samples artificially subjected to oxidative stress. To be used as an oxidation marker, it should be possible to determine it reliably and accurately under ambient conditions, especially in aqueous biopharmaceutical formulations, without the artificial influence of supplemented catalysts, so as to be able to distinguish between different degradation pathways of polysorbate 20. In this context, it is also important to ensure that formulation excipients, typically present in aqueous biopharmaceutical formulations for example, do not interfere with the determination of polyethylene glycol-6-laurate. Indeed, we find that the presence of polyethylene glycol-6-laurate as an oxidation marker in the oxidative degradation of polysorbate 20 not only applies to artificially generated oxidative degradation, but this oxidation marker also occurs during the naturally occurring oxidative degradation of polysorbate 20 in aqueous formulations. We also find that the presence of various common formulation excipients in the aqueous formulations does not interfere with the determination of polyethylene glycol-6-laurate or in any way adversely affect the method of the present invention. Furthermore, the presence of other components, such as one or more proteins, also does not interfere with the determination of polyethylene glycol-6-laurate.
[0108] Proteins which may be advantageously used are, for example, selected from monoclonal antibodies, polyclonal antibodies, monospecific antibodies, multispecific antibodies, single chain antibodies or antibody fragments thereof, such as Fv, scFv, Fab, Fab', scFab, F(ab')2, Fab2, Fc and Fc' fragments, heavy and light immunoglobulin chains and their constant, variable or hypervariable regions and Fv and Fd fragments, diabodies, triabodies, scFv-Fc, minibodies or single domain antibodies, or mixtures thereof. Thus, the aqueous formulation may be an aqueous formulation containing conventional formulation excipients. It may be an aqueous formulation that can be used in the field of biopharmaceuticals, containing one or more excipients and optionally one or more other components, such as a protein.
[0109] Aqueous formulations as biopharmaceutical preparations According to one embodiment, the aqueous formulation may be an aqueous biopharmaceutical formulation. The aqueous biopharmaceutical formulation may contain pharmaceutically acceptable polysorbate 20, one or more pharmaceutically acceptable excipients, and optionally one or more active pharmaceutical ingredients (APIs). Examples of pharmaceutically acceptable polysorbate 20 have been described above. Pharmaceutically acceptable excipients that can be used in biopharmaceutical formulations are well known to those skilled in the art. The one or more active pharmaceutical ingredients (API) may be, for example, one or more proteins selected from therapeutic proteins used in the prevention or treatment of a disease or disorder. Thus, the oxidation markers can also be used in the context of aqueous biopharmaceutical formulations to determine whether oxidative degradation of polysorbate 20 has already occurred. That the method of the present invention also works with aqueous biopharmaceutical formulations is demonstrated and confirmed from the following studies.
[0110] The oxidative degradation of polysorbate 20 is investigated in several aqueous biopharmaceutical formulations. For this purpose, two different monoclonal antibody formulations, designated mAb-1 and mAb-2 formulations, as well as a placebo for the mAb-1 formulation, were used, which is the same aqueous biopharmaceutical formulation as the mAb-1 formulation, but without the monoclonal antibody mAb-1. Both the mAb formulations as well as the placebo formulation are aqueous formulations and contain pharma- ceutically acceptable polysorbates and pharma- ceutically acceptable excipients. Detailed information on the mAb-1 and mAb-2 monoclonal antibodies, as well as the composition of the aqueous biopharmaceutical formulations, i.e., mAb-1 and mAb-2 formulations and placebo for mAb-1 formulation, can be found in the Experimental section, chapter "1.1 Materials", point "a) Monoclonal Antibodies". In addition, the mAb-1 used in the mAb-1 formulation was prepared by different variants, namely variant A and variant B, whereby the downstream process of variant B was optimized for the removal of host cell impurities. Therefore, the mAb-1 formulation was tested in two alternatives, variants A and B.
[0111] The mAb-2 used in the mAb-2 formulation was also prepared in different variants, namely variant A and variant B. Variant A was carried out at laboratory scale and variant B was carried out at a biopharmaceutical plant. Therefore, the mAb-2 formulation was also tested in two alternatives, variants A and B. Both monoclonal antibodies mAb-1 and mAb-2 are therapeutic proteins used in the prevention or treatment of a disease or disorder. To investigate the oxidative degradation of polysorbate 20 over time, the mAb-1 formulation described above was stored for 3 months at room temperature (25° C.) without the addition of any artificial oxidation catalyst such as AAPH; the mAb-2 formulation was stored for 6 months at room temperature (25° C.) without the addition of any artificial oxidation catalyst such as AAPH.
[0112] First, polysorbate 20 concentrations and relative levels of the polyethylene glycol-6-laurate oxidation marker for the mAB-1 formulation and the corresponding placebo formulation were determined at different sampling times, and the results are shown in Figures 4A and 4B. Figure 4A shows the polysorbate 20 concentration [mg / mL] plotted against time [months] as determined by HPLC-CAD analysis. Details of the HPLC-CAD analysis can be found in the experimental section, chapter "1.2 Methods", point "d) Quantification of polysorbate 20 via high performance liquid chromatography charged aerosol detection (HPLC-CAD)". Figure 4B shows the relative levels of the oxidation marker polyethylene glycol-6-laurate based on relative peak area [%] plotted against time [months] as determined by the liquid chromatography mass spectrometry (LC-MS) based method of the present invention. For method details, please refer to the experimental section, chapter "1.2 Methods", point "c) Quantification of the oxidation marker PEG-6 laurate (P6L) via liquid chromatography mass spectrometry (LCMS P6L).
[0113] In Figure 4A, both mAb1 formulations show reduced polysorbate 20 levels, despite the different reaction kinetics, even though mAb-1 is produced using two different variants, A and B, respectively, and the placebo formulation also shows reduced polysorbate 20 levels (curve with triangles). In detail, in Figure 4A, the mAb-1 formulation resulting from variant A (curve with circles: mAb-1 (variant A)) shows a significant loss of total polysorbate 20 during storage as measured by HPLC-CAD. In contrast to variant A, variant B (curve with squares: mAb-1 (variant B)) shows minimal degradation of polysorbate 20, resulting in a mAb-1 formulation that is substantially stable during storage, since the downstream process was optimized for the removal of host cell impurities.
[0114] In FIG. 4B, only the placebo formulation (curve with triangles: placebo vs. mAb-1 formulation) shows an increase in the relative level of the polyethylene glycol-6-laurate oxidation marker. Moreover, as can be seen in FIG. 4B, both variants A and B of the mAb-1 formulation are equivalent and do not show an increase in the relative level of polyethylene glycol-6-laurate. However, when compared to the corresponding placebo formulation, a significant loss of polysorbate 20 is observed in the placebo formulation (FIG. 4A: curve with triangles) together with a concomitant increase in the relative level of polyethylene glycol-6-laurate (FIG. 4B: curve with triangles as well). The loss of polysorbate 20 should be due to oxidative degradation, since degradation caused by host cell proteins (HCPs) can be excluded in the placebo formulation. Moreover, oxidative degradation of polysorbate 20 does not occur in both mAb-1 formulations, since both variants A and B of the mAb-1 formulation do not show an increase in the relative levels of polyethylene glycol-6-laurate shown in Figure 4B. Furthermore, it can be assumed from Figures 4A and 4B that polysorbate 20 in the mAb-1 formulation, variant A, is subject to hydrolysis rather than oxidative degradation. As a result, Figures 4A and 4B clearly demonstrate that it is possible to distinguish between non-oxidative and oxidative degradation of Polysorbate 20 based on the relative levels of polyethylene glycol-6-laurate found.
[0115] Indeed, the stability study confirms the above conclusions. For this reason, a stability study was performed. Placebo and mAb-1 formulations against mAb-1 formulations prepared by variant A were analyzed using a liquid chromatography mass spectrometry (LC-MS) method. The data found are shown in the bar graphs of Figures 5A and 5B. Figures 5A and 5B show a 3-month stability study of formulations, with relative peak areas plotted against time [months] analyzed by LC-MS-POE and LC-MS-FFA by the liquid chromatography mass spectrometry (LC-MS)-based method embodiment of the present invention. Details of the LC-MS-POE and LC-MS-FFA methods are described in the experimental section (chapter "1.2 Methods", point "a) Screening of intact polysorbate 20 species via liquid chromatography-mass spectrometry (LC-MS POE)" and chapter "1.2 Methods", point "e) Determination of free fatty acids (FFAs) via liquid chromatography-mass spectrometry (LC-MS FFAs)"). Data for LC-MS-FFA are not shown. Figure 5A shows a block diagram of the content levels of native polysorbate 20 species as relative peak area [%] over a 3-month period representing the stability study of placebo versus mAb-1 formulations, and the native polysorbate 20 species are compounds present in polysorbate 20 before oxidative polysorbate 20 degradation occurs (reference, start) and during the oxidative degradation of polysorbate 20 observed for up to 3 months. The native polysorbate 20 species analyzed are again POE-sorbitan mono C12, POE-isosorbide mono C12, POE mono C12 and POE-sorbitan di C12, whose chemical structures are shown in Figure 3 (see
[10] ).
[0116] In Figures 5A and 5B, the first sample of the aqueous formulation is not taken as a reference sample, but another reference sample is used. The other reference sample is polysorbate 20 (commercial raw material) in an aqueous solution (not shown in the figure). For the determination of the relative peak area, the normalization procedure described is used. Because another reference sample is used, the relative peak area of the starting sample is not 100%. Figure 5B shows a block diagram of the relative levels of intact polysorbate 20 species as relative peak area [%] over a 3 month period representing a stability study for the mAb-1 formulation (variant A). Comparison of the intact polysorbate 20 species profile over the stability storage period shows a reduction of all species for the mAb-1 formulation (variant A) in Figure 5B, with only the corresponding placebo formulation showing a clear reduction of POE-sorbitan di-C12. The greater decrease in POE-sorbitan diC12 in polysorbate 20 in the placebo formulation (Figure 5A) compared to the mAb-1 formulation (Figure 5B) can be explained by the fact that diesterified polysorbate 20 species such as POE-sorbitan diC12 are less susceptible to enzymatic degradation due to steric hindrance, whereas they typically decrease at a faster rate during oxidative degradation (see Figure 5A) [1].
[0117] With the increased relative levels of polyethylene glycol-6-laurate in the placebo formulation as shown in FIG. 4B, this clearly indicates oxidative degradation of polysorbate 20 in the placebo formulation. Therefore, polyethylene glycol-6-laurate can also serve as a marker substance for the presence of oxidative degradation pathways in biopharmaceutical preparations. Thus, the relative levels of polyethylene glycol-6-laurate can be detected in these aqueous biopharmaceutical formulations under appropriate storage conditions without artificial oxidation catalysts, indicating that polyethylene glycol-6-laurate is also a reliable oxidation marker in natural biopharmaceutical formulations.
[0118] Many other experiments have been performed and all have confirmed that polyethylene glycol-6-laurate is a reliable oxidation marker for the oxidative degradation of polysorbate 20 and can be determined in aqueous biopharmaceutical formulations independent of the presence of conventional excipients and / or active pharmaceutical ingredients (APIs). To demonstrate that polyethylene glycol-6-laurate is an effective and reliable oxidation marker for natural aqueous biopharmaceutical formulations, the results of another monoclonal antibody containing aqueous biopharmaceutical formulation, i.e., mAb-2 formulation, are shown below (detailed information on the composition of the monoclonal antibody mAb-2 as well as the aqueous biopharmaceutical formulation, i.e., mAb-2 formulation, is given in the experimental section, chapter 1.1, point a)). In this case, a mAb-2 formulation was investigated, where mAb-2 is prepared by two different processes, variant A and variant B. Variant A was carried out on a laboratory scale and variant B was carried out in a biopharmaceutical plant. The data are shown in Figures 6A and 6B.
[0119] Figure 6A shows the polysorbate 20 concentration [mg / mL] plotted against time [months] as determined by HPLC-CAD analysis (for details see Experimental section, Chapter 1.2, point d)). Figure 6B shows the relative levels of polyethylene glycol-6-laurate oxidation markers based on relative peak area [%] plotted against time [months] as determined by a liquid chromatography-mass spectrometry (LC-MS) based method (for details see Experimental section, Chapter 1.2, point c)). As can be seen in Figure 6A, mAb-2 formulations prepared with variant A and variant B, respectively, show comparable rates of total polysorbate 20 degradation despite different kinetics. However, as shown in Figure 6B, an increase in the relative levels of polyethylene glycol-6-laurate was only detected in variant A of the mAb-2 formulation (curve with triangles), indicating that both variants differ in their degradation pathways, such that only variant A shows an increase in the relative levels of polyethylene glycol-6-laurate during stability storage, indicative of oxidative degradation of polysorbate 20.
[0120] Thus, Figures 6A and 6B also demonstrate that it is possible to distinguish between non-oxidative and oxidative degradation of polysorbate 20 in an aqueous biopharmaceutical formulation based on the relative levels of polyethylene glycol-6-laurate found. The determination of the relative levels of polyethylene glycol-6-laurate by its separation and detection is possible independent of the presence of one or more excipients and independent of the presence of one or more proteins, e.g., therapeutic proteins. This also corresponds well with the LC-MS characterization data for the stability study of mAb-2 formulation variants A and B found in LC-MS-POE and LC-MS-FFA (method details for LC-MS-POE and LC-MS-FFA are explained in the Experimental section, Chapter 1.2, point a) and Chapter 1.2, point e). Data for LC-MS-FFA are not shown.
[0121] The results are shown in Figure 7A (variant B) and Figure 7B (variant A). In Figures 7A and 7B, unlike Figures 5A and 5B, the first sample of the aqueous formulation under investigation is used as a reference sample. For the determination of the relative peak areas, the normalization procedure described is used. Since the first sample serves as the reference sample, the relative peak area of the starting sample is 100%. In Figures 7A and 7B, both variants of the mAb-2 formulation show a decrease in intact polysorbate 20 species. However, only variant A (Figure 7B) shows an increase in the relative levels of polyethylene glycol-6-laurate during stability storage, indicative of oxidative degradation of polysorbate 20 as shown in Figure 6B (curve with triangles). Oxidative degradation is confirmed by the decrease in the diesterified species POE-sorbitan di-C12 for variant A of the mAb-2 formulation (Figure 7B), as diesterified polysorbate 20 species are less susceptible to enzymatic degradation due to steric hindrance, which typically shows a decrease during oxidative degradation [1].
[0122] As further evidence that polyethylene glycol-6-laurate is indeed a reliable oxidation marker for natural aqueous biopharmaceutical formulations, Figures 8A and 8B show the results of another monoclonal antibody containing aqueous biopharmaceutical formulation, namely mAb-4 formulation and placebo against mAb-4 formulation (detailed information on the composition and stability conditions of monoclonal antibody mAb-4 as well as aqueous biopharmaceutical and placebo formulations are given in the Experimental section, Chapter 1.1, points a) and b)). Figure 8A shows the polysorbate 20 concentration [mg / mL] plotted against time [months] as determined by HPLC-CAD analysis (for details see Experimental section, Chapter 1.2, point d)). Figure 8B shows the relative levels of polyethylene glycol-6-laurate oxidation markers based on relative peak area [%] plotted against time [months] as determined by a liquid chromatography-mass spectrometry (LC-MS) based method (for details see Experimental section, Chapter 1.2, point c)). As can be seen in Figure 8A, the mAb-4 formulation (curve with triangles) shows virtually no decrease in the concentration of intact polysorbate 20 species, while the placebo (curve with dots) for the antibody-free mAb-4 formulation shows a significant decrease in the concentration of intact polysorbate 20 species during stable storage. Thus, the two curves show that only in the placebo formulation is there evident degradation of polysorbate 20, with polysorbate 20 being virtually completely degraded after six months.
[0123] Figure 8B shows that, by the LC-MS-based method of the present invention, polyethylene glycol-6-laurate is formed as a degradation product of polysorbate 20 to a greater extent in the placebo formulation, whereas the mAb formulation shows little increase in PEG-6-laurate levels. Thus, the curves in Figures 8A and 8B are temporally uncorrelated with each other. Thus, polyethylene glycol-6-laurate serves as a true oxidation marker not only under artificial conditions but also in natural aqueous formulations, such as biopharmaceutical preparations and stability tests of samples. The marker substance, and in particular its relative level, can indicate oxidative degradation both in the presence and absence of one or more active pharmaceutical ingredients (APIs), such as proteins, in particular monoclonal antibodies. The oxidation marker polyethylene glycol-6-laurate is also capable of distinguishing between non-oxidative and oxidative degradation of polysorbate 20 in aqueous formulations, particularly aqueous biopharmaceutical formulations, with or without one or more active pharmaceutical ingredients (APIs) and with or without one or more excipients.
[0124] Implementation of the method Therefore, the liquid chromatography-mass spectrometry (LC-MS) based method of the present invention was adapted to be used for the separation, detection and identification of polyethylene glycol-6-laurate, particularly in terms of relative peak area or its relative level and optional quantification of polyethylene glycol-6-laurate. To verify that the liquid chromatography-mass spectrometry (LC-MS) based method is a feasible and reliable test method, the method was investigated for linearity, specificity, authenticity, robustness and precision according to known data in the art [11, 12]. It was found to be a suitable method that provides linear, precise, accurate, specific and reliable results on the relative levels of polyethylene glycol-6-laurate present, details of which are given in the experimental section (chapter "2. Characterization of the LC-MS P6L method performance" and Figure 8).
[0125] Further objects of the invention According to the present invention, there is provided a process for producing a recombinant protein (third method), comprising the steps of: a) culturing in a cell culture a eukaryotic cell expressing the recombinant protein; b) harvesting the recombinant protein; c) purifying the recombinant protein using an aqueous formulation; (d) formulating the recombinant protein into a pharma- ceutically acceptable aqueous formulation suitable for administration using polysorbate 20; and step e) of obtaining at least one sample of the pharma- ceutically acceptable aqueous formulation of step d); Including, Also provided is a process, the process (third method) further comprising carrying out the method (first or second) for determining the extent of oxidative degradation of polysorbate 20 disclosed in the present invention on the sample obtained in step e).
[0126] According to one embodiment, the above process for producing a recombinant protein (third method) comprises obtaining at least one sample containing the recombinant protein and polysorbate 20 in step e) as described above, the sample from step d) being a drug substance sample or a drug product sample. The recombinant protein of the above process of the present invention is produced in eukaryotic cells following expression, and the recombinant protein is harvested and further purified. The recombinant protein can be recovered from the culture medium as a secreted protein in harvested cell culture fluid (HCCF) or from cell lysate (i.e., a fluid containing the contents of cells lysed by any means, including but not limited to enzymatic, chemical, osmotic, mechanical, and / or physical disruption of cell membranes and any cell walls) and purified using techniques well known in the art. The recombinant protein is then formulated into a pharma-ceutically acceptable aqueous formulation suitable for administration using polysorbate 20, and at least one sample containing the recombinant protein and the formulated recombinant protein polysorbate 20 is obtained.
[0127] The above-mentioned process (third method of the invention) further comprises carrying out the method for determining the degree of oxidative degradation of polysorbate 20 disclosed in the present invention (first or second method of the invention) on the sample obtained in step e). The present invention is also directed to methods related to the oxidative degradation of polysorbate 20 in aqueous formulations or several aqueous formulations containing polysorbate 20, respectively, and in particular to the use of polyethylene glycol-6-laurate as an oxidation marker in the (first or second) methods disclosed herein. The subject of the present invention is also the use of the (first or second) method disclosed herein for determining the oxidative degradation of polysorbate 20 in an aqueous formulation as a stability test during the development, manufacture, shelf-life or storage of an aqueous formulation or several aqueous formulations, respectively, containing polysorbate 20.
[0128] The advantages of the present invention are manifold. Polysorbate 20 is particularly important due to its known function of stabilizing components present in aqueous formulations, so its known autoxidation leads to oxidative degradation and consequent damage of aqueous formulations. Monitoring the oxidative degradation of polysorbate 20 is now possible for the first time using a compound that indicates degradation. This is polyethylene glycol-6-laurate, an oxidative marker of the oxidative degradation of polysorbate 20. In the art, oxidative markers for polysorbate 20 have been hypothesized based on various proposed degradation mechanisms, but these have not yet been experimentally identified as true components of the oxidative degradation process of polysorbate 20. It can be demonstrated that polyethylene glycol-6-laurate is indeed an oxidation marker for solutions containing polysorbate 20 when autoxidation of polysorbate 20 occurs artificially by the addition of an oxidation catalyst. However, polyethylene glycol-6-laurate specific for oxidative degradation also occurs during storage of aqueous formulations containing polysorbate 20 without the addition of an oxidation catalyst, i.e., when oxidative degradation of polysorbate 20 occurs naturally. Thus, polyethylene glycol-6-laurate not only serves as a robust oxidation marker for artificially stressed samples, but is also a reliable and accurate oxidation marker in aqueous formulations, such as aqueous biopharmaceutical formulations.
[0129] According to the present invention, a liquid chromatography mass spectrometry (LC-MS) based method is provided that allows for reliable determination by separation and detection of the relative levels of the oxidation marker polyethylene glycol-6-laurate in aqueous formulations. The liquid chromatography mass spectrometry (LC-MS) based method is based on existing methods, modified and adapted for the oxidation marker polyethylene glycol-6-laurate according to the present invention. The liquid chromatography mass spectrometry (LC-MS) based method for determining the relative levels of polyethylene glycol-6-laurate works in simple aqueous solutions containing only polysorbate 20, as well as in highly complex aqueous formulations containing excipients, with and without active pharmaceutical ingredients (APIs), and in biopharmaceutical formulations. Biopharmaceutical formulations can also contain typical excipients, such as buffers, sugars, stabilizers, etc., which do not interfere with the determination of the relative levels of the oxidation markers.
[0130] Regardless of the presence of oxidation markers, the occurrence of oxidative degradation in polysorbate 20 has been confirmed in stability studies independent of the methods of the present invention. In such stability studies, a decrease in all intact polysorbate 20 species was observed, with a significant decrease in one diester species. These diester species are known to be less susceptible to enzymatic degradation due to steric hindrance, but typically decrease at a higher rate during oxidative degradation, thus confirming oxidative degradation. Thus, liquid chromatography-mass spectrometry (LC-MS) based analytical methods make it possible to monitor the relative levels of polyethylene glycol-6-laurate even in complex aqueous formulations, and monitoring the relative levels of polyethylene glycol-6-laurate as an oxidation marker allows for differentiation between hydrolytic and oxidative degradation of polysorbate 20 in aqueous formulations. Indeed, the liquid chromatography mass spectrometry (LC-MS) based method developed in the present invention allows the relative levels of polyethylene glycol-6-laurate to be measured linearly, precisely and accurately, even in complex aqueous formulations.
[0131] The increase in the relative level of the marker substance polyethylene glycol-6-laurate correlates well with the loss of polysorbate 20 during oxidative degradation, both when oxidation is artificially induced and when oxidation of polysorbate 20 occurs naturally. Thus, according to the present invention, it is possible to distinguish between non-oxidative and oxidative degradation in the degradation of polysorbate 20 in aqueous formulations. If one observes degradation of polysorbate 20 that correlates with a concomitant increase in the relative level of polyethylene glycol-6-laurate, then oxidative degradation of polysorbate 20 is clearly present. If one observes degradation of polysorbate 20, but without a concomitant increase in the relative level of polyethylene glycol-6-laurate, then non-oxidative degradation of polysorbate 20 is clearly present. Up to now, no analytical tools have been described in the prior art that allow the differentiation between hydrolysis and oxidative degradation of polysorbate 20 by direct analytical means. Thus, the relative levels of polyethylene glycol-6-laurate serve as a marker for the presence of oxidative degradation pathways in the aqueous formulation. Oxidative markers can also indicate oxidative degradation in aqueous biopharmaceutical formulations in both the presence and absence of active pharmaceutical ingredients (APIs), such as proteins, e.g., monoclonal antibodies. Additional quantification of the oxidation marker polyethylene glycol-6-laurate also makes it possible to estimate the degree of oxidative degradation and therefore to draw conclusions about the polysorbate 20 that remains present in the aqueous formulation.
[0132] Based on the methods of the present invention, it is further possible to make predictions about the expected oxidative degradation of polysorbate 20 in the same or very similar aqueous formulations based on an estimation of the oxidative degradation of polysorbate 20 in the aqueous formulation at a particular time. This can be particularly important in the development of aqueous formulations, especially aqueous biopharmaceutical formulations. According to the invention, it is also possible to determine the degree of oxidative degradation of polysorbate 20 in several aqueous formulations, in particular each aqueous formulation containing the same amount of polysorbate 20. This allows for sequential tests to be performed on many aqueous formulations, allowing for example quality or stability control. In this way, optimized formulation compositions can also be created. Thus, the present invention provides the first time method to use an analytical method to monitor, detect, and optionally quantify a previously undescribed analyte, namely polyethylene glycol-6-laurate, in an aqueous formulation, such as an aqueous biopharmaceutical formulation, to observe and estimate the oxidative degradation of polysorbate 20.
[0133] List of abbreviations [Table 1] The experimental details carried out are as follows: The following experimental details should not be construed as limitations of the present invention.
[0134] experiment 1. Materials and Methods 1.1 Material All experiments were performed with polysorbate 20 high purity (PS20 HP) (Croda, Edison, NJ, USA). Polyethylene glycol-6-laurate (PEG-6 laurate) was synthesized by ChiroBlock GmbH, Bitterfeld-Wolfen, Germany) with a purity of 95%. 24 H 48 O 8 Synthetic polyethylene glycol-6-laurate, molecular weight 464.65 g / mol, was used. All other chemicals used were of analytical grade and obtained from commercial sources.
[0135] a) Monoclonal antibodies Four monoclonal antibodies (mAbs) in specific formulations were used: The mAb-1 formulation contains mAb-1, which is an IgG1 type antibody. The mAb-1 used in the mAb-1 formulation was prepared by different variants, namely variant A and variant B, whereby the downstream process of variant B was optimized for the removal of host cell impurities. Variant A of the mAb-1 formulation was concentrated at 65 mg / mL and contained 0.200 g / mL polysorbate 20, 11.4 mM L-histidine, 12.8 mM L-histidine HCl + 2H 2 Formulated in 0, 213.0 mM mannitol, 28.3 mM sucrose, pH 6.0. Variant B of the mAb-1 formulation was concentrated at 65 mg / mL and contained 0.200 g / mL polysorbate 20, 11.4 mM L-histidine, 12.8 mM L-histidine HCl + 2H 2 The mixture is formulated in 0, 43.9 mM mannitol, 184 mM sucrose, pH 6.0.
[0136] The mAb-2 formulation consists of mAb-2, an IgG1 type antibody, concentrated at 50 mg / mL and formulated in 0.400 mg / mL polysorbate 20, 4.23 mM acetic acid, 15.8 mM sodium acetate trihydrate, 220 mM glycine, 20 mM trehalose dihydrate, pH 5.5. The mAb-3 formulation consists of mAb-3, an IgG1 type antibody, concentrated at 60 mg / mL and formulated in 0.400 mg / mL polysorbate 20, 45 mM acetate, 150 mM sucrose, 25 mM L-arginine HCL, pH 5.5. The placebo for the mAb-1 formulation was 0.200 g / mL polysorbate 20, 11.4 mM L-histidine, 12.8 mM L-histidine HCl + 2H 2 O, 43.9 mM mannitol, 184 mM sucrose, pH 6.0, and no mAb-1. The mAb-4 formulation consists of mAb-4, an IgG4 type antibody, concentrated at 80 mg / mL and formulated in 0.400 mg / mL polysorbate 20, 10 mM acetate, 240 mM trehalose, pH 5.2. The placebo for the mAb-4 formulation was a formulation containing 0.400 g / mL polysorbate 20, 10 mM acetate, 240 mM trehalose, pH 5.2, and no mAb-4.
[0137] b) mAb stability studies Stability studies of mAb-1 and its corresponding placebo were performed in 20R glass vials (content: 20 mL) at 25° C. (room temperature) storage conditions for 3 months. Stability studies of mAb-2 were performed in 20R glass vials at 25° C. (room temperature) / 60% RH (relative humidity) storage conditions for 6 months. Stability studies of mAb-4 and its corresponding placebo were conducted in 6R glass vials (content: 3 mL) at storage conditions of 25° C. (room temperature) / 60% RH (relative humidity) for 6 months.
[0138] c) Preparation of artificially stressed polysorbate 20 samples Experiments for identification of PEG-6-laurate: 1.5 mM 2,2'-azobis-2-methyl-propanimidamide, dihydrochloride (AAPH) was added to a 0.040 mg / mL aqueous polysorbate 20 solution. The polysorbate 20 solution was stressed at 50°C for 40 hours. For correlation with total polysorbate 20 degradation: 1.5 mM 2,2'-azobis-2-methyl-propanimidamide, dihydrochloride (AAPH) was added to a 0.040 mg / mL aqueous polysorbate 20 solution. The polysorbate 20 solution was stressed for 35 hours at 50° C. After 0, 1, 3, 8, 12, 24, and 35 hours, samples were taken from the solution and immediately frozen at −20° C. to stop degradation at each time point.
[0139] 1.2 Method a) Screening of intact polysorbate 20 species via liquid chromatography-mass spectrometry (LC-MS POE) Liquid chromatography: The characterization method for polysorbates used reversed-phase chromatography (Kinetex XB-C C18, 2.6 μm, 2.1×150 mm, Phenomenex) operated at 50° C. with a flow rate of 0.250 mL / min for the separation of polysorbate species in order of their increasing hydrophobicity (1200 series, Agilent) using water as mobile phase (MP) A and 1% formic acid in acetonitrile (ACN) as mobile phase (MP) B. The analytical gradient started with 5% MP B until 25 min, with a linear ramp to 100% MP B at 20 min. MP B was reduced to 5% at 25.1 min with a 0.1 min ramp, followed by a column wash and re-equilibration step with 5% MP B until 30 min. The column load was typically 1-2 μg polysorbate sample in ACN.
[0140] Mass spectrometry: The separated species were then ionized with a heated electrospray ionization (HESI) source (Ion Max ion source with HESI probe, Thermo Fisher Scientific). The instrument was operated in positive ionization mode at 310°C with a source voltage of 4 kV. Fatty acid specific fragments generated by subsequent in-source fragmentation were detected with a mass spectrometer (LTQ, Thermo Fisher Scientific). The capillary temperature was 275°C and operated at 43 kV. Full scan spectra were collected over an m / z range of 100-2000 amu (atomic mass units). The fatty acid esters of polysorbate 20 were evaluated by generating extracted ion chromatograms (EIC or XIC) from the full scan data to obtain peak areas for selected compounds using LCquan™ (software for quantitative analysis of liquid chromatography). Fragments of species containing the same fatty acid differed by their characteristic retention times. b) High resolution mass spectrometry (HR-MS) Liquid chromatography: For chromatographic conditions see section a) above (LC-MS POE).
[0141] Mass spectrometry: The separated species were ionized with a heated electrospray ionization (HESI) source (Ion Max ion source with HESI probe, Thermo Fisher Scientific). The instrument was operated in positive ionization mode at 310 °C with a source voltage of 4 kV. Fatty acid-specific fragments generated by subsequent in-source fragmentation were detected with a mass spectrometer (LTQ Orbitrap XL, Thermo Fisher Scientific). The capillary temperature was 275 °C and operated at 9 kV. Full scan spectra with a resolution of 30000 were collected over the m / z range of 100.0-2000.0 amu. Structures were identified via exact determination of monoisotopic peaks.
[0142] c) Quantification of the oxidation marker PEG-6 laurate (P6L) via liquid chromatography mass spectrometry (LCMS P6L) Liquid chromatography: For chromatographic conditions of the LC-MS P6L method, see section a) above (LC-MS POE). The column load was 1 μg of polysorbate sample in ACN.
[0143] Mass spectrometry: The separated species were then ionized with a heated electrospray ionization (HESI) source (Ion Max ion source with HESI probe, Thermo Fisher Scientific). The instrument was operated in positive ionization mode at 310°C with a source voltage of 4 kV. The generated ions were detected with a mass spectrometer (LTQ, Thermo Fisher Scientific). The capillary temperature was 275°C and operated at 43 kV. Full scan spectra were collected over an m / z range of 300.0-550.0 amu. PEG-6-laurate was evaluated by generating extracted ion chromatograms (EICs) from the full scan data to obtain peak areas of selected compounds using LCquan™ (software for quantitative analysis of liquid chromatography).
[0144] d) Quantification of Polysorbate 20 via High Performance Liquid Chromatography Charged Aerosol Detection (HPLC-CAD) mAb and placebo samples were diluted 1:2 with water to polysorbate 20 concentrations within the calibration range of the method. An external calibration curve was prepared using aqueous polysorbate 20 solution. The injection volume was 10 μL. HPLC-CAD was measured on a CAD Veo RS (Thermo Fisher Scientific) coupled to an Agilent 1290 LC system (Agilent). Chromatographic separation was performed with the aid of a mixed-mode column Oasis MAX online (20 × 2.1 mm, 30 μm, water) at 1 ml / mL and a column temperature of 30 °C. MP A consisted of 10 mM ammonium formate, 20% 2-propanol, pH 3; MP B consisted of acetonitrile / 2-propanol 50 / 50% (v / v). The analytical gradient started with 0% MP B isocratic followed by a 0.1 min ramp to 10% MP B in 14.0–14.1 min. At 20 min, MPB was increased to 0% and re-equilibrated until 25 min. The CAD was operated at an evaporation temperature of 70° C., a power function of 1.0, a filter constant of 5 s, and a data collection rate of 10 Hz. Recorded chromatograms were integrated and polysorbate 20 concentrations were calculated using quadratic regression (Empower).
[0145] e) Determination of free fatty acids (FFA) via liquid chromatography mass spectrometry (LC-MS FFA) Characterization of polysorbates was via LC-MS to determine free fatty acids, namely lauric, myristic, palmitic, stearic and oleic acids. Samples of mAb and polysorbate 20 were diluted with water to a final polysorbate 20 concentration of 0.040 mg / mL. Injection volume was 20 μL. For chromatographic separation, a RP column (Jupiter C18, 3 μm, 2×150 mm, Phenomenex) at 50° C. and a HPLC system (LC-30AD, SIL-30 AC, Shimadzu) at a flow rate of 0.300 mL / min were used. 10 mM ammonium acetate was used as MB A and 2-propanol as MB. The analytical gradient started with 50% MP B until 2.5 min, with a linear ramp to 100% MP B in 1 min. At 3.5 min, MP B was increased to 100% with a ramp of 0.1 min. MP B was decreased to 50% with a 0.1 min ramp in 5 min, followed by a column wash and re-equilibration step at 50% MP B until 11 min.
[0146] FFAs were ionized with HESI (Ion Max ion source with HESI probe, Thermo Fisher Scientific) and analyzed with a mass spectrometer (LTQ, Thermo Fisher Scientific) in negative mode. The instrument was operated in positive ionization mode at 310 °C with a source voltage of 3.5 kV. Fatty acids were detected with a mass spectrometer (LTQ, Thermo Fisher Scientific). The capillary temperature was 275 °C and operated at -49 kV. Full scan spectra were collected over an m / z range of 150.0-300.0 amu. Finally, extracted ion chromatograms (EICs) were generated from the full scan data using LCquan™ (software for quantitative analysis of liquid chromatography). Quantification determinations were performed by using FFA calibration standards (10-1500 ng / mL).
[0147] 2. Characterization of LC-MS P6L Method Implementation To verify whether the LC-MS based method is a realiable and suitable test method, the method was investigated for linearity, specificity, accuracy, and precision by procedures well known in the art. Linearity: First, the linearity of the method was evaluated using the coefficient of determination (R 2 The R of the standard curve of 1 to 25 ng / mL PEG-6-laurate was evaluated. 2 The evaluation reveals good linearity of the method (R 2 =0.9979). The standard curve for the LC-MS P6L method is shown in Figure 8. Figure 8 shows the standard curve for PEG-6-laurate by plotting the detection area of the LC-MS analysis (LC-MS P6L) (x-axis) against the concentration of the standard solutions (1-25 ng / mL) (y-axis). The linear fit of the standard curve yielded a coefficient of determination (R) of 0.9979. 2 ) Thus, the method has good linearity.
[0148] Specificity: Specificity analysis using mAb-3 spiked with synthetic PEG-6-laurate and placebo for mAb-3 revealed no interference of API, polysorbate 20 or other formulation compounds with the signal of spiked PEG-6-laurate. That is, PEG-6-laurate was detected in the spiked samples, but no interfering signal was detected in the control solutions. Only PEG-6-laurate was detected in the spiked samples, providing the specificity of the LC-MS P6L method. The results are summarized in Table 1.
[0149] Precision and accuracy: The evaluation of precision and accuracy was carried out through the analysis of NBE solutions spiked with 2.5 ng / nL and 20 ng / nL synthetic PEG-6-laurate, with three replicates prepared independently for each concentration (n=3 for each PEG-6-laurate concentration). The results of the evaluation of precision show low relative standard deviations (%RSD) for both levels of PEG-6-laurate samples (%RSD for 2.5 ng / mL PEG-6-laurate: 2%; %RSD for 20 ng / mL: 3%). Furthermore, the relative average recoveries of both PEG-6-laurate samples for the target levels (spiked concentrations) show good results, varying between 90 and 104%, indicating good precision and accuracy of the LC-MS P6L method. The results are also outlined in Table 1. Table 1 below shows the results of the evaluation of the specificity, precision and accuracy parameters of the method for detecting and quantifying PEG-6-laurate (P6L).
[0150] [Table 2]
[0151] In summary, the characterization of the LC-MS based method of the present invention for the quantification of PEG-6-laurate shows good performance and can determine specific, precise and accurate levels of PEG-6-laurate in NBE solutions. The method LC-MS P6L can then be used to identify critical PEG-6-laurate thresholds in NBE, thereby providing an analytical tool during formulation and process development of aqueous formulations such as biopharmaceuticals.
[0152] References TIFF2024544257000006.tif95170 TIFF2024544257000007.tif120166The present invention includes aspects disclosed in the following sentences.
[0153] Sentence 1. Follow these steps: Step 1 of preparing a first sample of the aqueous formulation to be tested, which serves as a reference sample; Step 2 of preparing another sample of the aqueous formulation to be tested and any further samples; using a liquid chromatography-mass spectrometry based method to separate polyethylene glycol-6-laurate and determine the peak area of polyethylene glycol-6-laurate, an oxidation marker of oxidative degradation of polysorbate 20, from the reference sample from step 1, the other sample from step 2 and any further samples, respectively; determining a relative peak area of polyethylene glycol-6-laurate based on the peak area of polyethylene glycol-6-laurate of the other sample and each of any further samples relative to the peak area of polyethylene glycol-6-laurate of the reference sample, the relative peak area being proportional to the extent of oxidative degradation of polysorbate 20; and Step 4: Quantify the compound polyethylene glycol-6-laurate based on the relative peak areas of the other sample and each of the optional additional samples. A method for determining the extent of oxidative degradation of polysorbate 20 in an aqueous formulation containing polysorbate 20, comprising:
[0154] 2. The prepared reference sample is an aqueous solution containing polysorbate 20, and the content of polysorbate 20 is the same as that of the aqueous formulation to be tested; The method according to sentence 1. 3. In step 2, two, three or more further samples of the aqueous formulation containing polysorbate 20 are taken at successive time intervals T1, T2, T3.... which may be of the same or different length; The method according to sentence 1.
[0155] 4. The relative peak areas of polyethylene glycol-6-laurate for the other sample and any further samples from step 3 are - forming the obtained peak area difference by subtracting the peak area of polyethylene glycol-6-laurate of the reference sample from the peak area of polyethylene glycol-6-laurate of the other sample and of any further sample, respectively; or - normalizing the peak areas obtained, by setting the peak area of polyethylene glycol-6-laurate of the reference sample to 100% and calculating and normalizing the peak areas of polyethylene glycol-6-laurate of the other sample and any further samples, respectively, based thereon. Determined by The method according to sentence 1.
[0156] 5.Follow these steps: Step 1a of preparing a sample of each aqueous formulation to be tested; using a liquid chromatography and mass spectrometry based method to separate polyethylene glycol-6-laurate and determine the peak area of polyethylene glycol-6-laurate, an oxidation marker of the oxidative degradation of polysorbate 20, from each sample of step 1a; Step 2a of comparing the peak areas of the samples with each other, the change in the peak area of the samples being proportional to the degree of oxidative degradation of polysorbate 20; and The compound polyethylene glycol-6-laurate may be quantified based on the peak area obtained for each sample. Step 3a A method for determining the extent of oxidative degradation of polysorbate 20 in several aqueous formulations each containing polysorbate 20, particularly where each aqueous formulation contains the same amount of polysorbate 20.
[0157] 6. The relative peak areas of polyethylene glycol-6-laurate in each sample were - forming a difference of the obtained peak areas by subtracting the peak area of the polyethylene glycol-6-laurate of the sample obtained from the reference sample; or - normalizing the peak areas obtained, in which the peak area of polyethylene glycol-6-laurate of the sample obtained from the reference sample is set to 100%, and the peak area of polyethylene glycol-6-laurate of another sample is calculated and normalized based thereon; is determined relative to a reference sample by The method according to sentence 5.
[0158] 7. The following conditions: - a polar solvent is added to the polysorbate-containing sample to be investigated before carrying out liquid chromatography, in particular a solvent used in liquid chromatography; - liquid chromatography is used as separation chromatography, in particular in the form of column chromatography, more particularly as reversed-phase chromatography; - liquid chromatography is used as high performance liquid chromatography and gradient elution may be used; - liquid chromatography is used as ultra-performance liquid chromatography and gradient elution may be used; - the mass spectrometry method is selected to be a high resolution mass spectrometry method, especially for the purpose of structure elucidation; - the polyethylene glycol-6-laurate is separated by liquid chromatography using hydrophobicity; and / or - Quantification of step 4 or step 3a is performed with external calibration using a standard solution of polyethylene glycol-6-laurate Satisfy one, two or more of the following: A method as described in any one of sentences 1 to 6 above.
[0159] 8. For data evaluation of liquid chromatography-mass spectrometry based methods, extracted ion chromatograms are generated from mass-to-charge ratios that include a range of about 487 amu, in particular a range of 486.5 to 487.5 amu; A method as described in any one of sentences 1 to 7 above. 9. Step 5, step 5' or step 4a includes estimating to what extent polysorbate 20 has already been oxidatively degraded in the sample based on an inverse relationship between polyethylene glycol-6-laurate levels and polysorbate 20 levels. A method as described in any one of sentences 1 to 8 above. 10. The aqueous biopharmaceutical formulation is used as an aqueous formulation; A method as described in any one of sentences 1 to 9 above. 11. The polysorbate 20 present is - intended for pharmaceutical use, in particular for use in drugs; and / or - suitable for parenteral administration; A method as described in any one of sentences 1 to 10 above.
[0160] 12. The aqueous formulation comprises one or more proteins, the proteins may be selected from monoclonal antibodies, polyclonal antibodies, monospecific antibodies, multispecific antibodies, single chain antibodies or antibody fragments thereof, such as Fv, scFv, Fab, Fab', scFab, F(ab')2, Fab2, Fc and Fc' fragments, heavy and light immunoglobulin chains and their constant, variable or hypervariable regions and Fv and Fd fragments, bispecific antibodies, trispecific antibodies, scFv-Fc, minibodies, or single domain antibodies, or mixtures thereof; The protein may be selected from therapeutic proteins used in the prevention or treatment of a disease or disorder; A method as described in any one of sentences 1 to 11 above.
[0161] 13. A process for producing a recombinant protein comprising the steps of: a) culturing a eukaryotic cell expressing the recombinant protein in a cell culture; b) harvesting the recombinant protein; c) purifying the recombinant protein using the aqueous formulation; and Step d of formulating the recombinant protein using polysorbate 20 into a pharma- ceutically acceptable aqueous formulation suitable for administration; step e) of obtaining at least one sample containing the recombinant protein and polysorbate 20 from step d); Including, carrying out a method for detecting oxidative degradation of polysorbate 20 according to any one of the preceding sentences 1 to 9 in the sample obtained in step e), wherein the sample from step d) may be a drug substance sample or a drug product sample, process.
[0162] 14. Use of polyethylene glycol-6-laurate as an oxidation marker in a method for determining the degree of oxidative degradation of polysorbate 20 in an aqueous formulation or in several aqueous formulations each containing polysorbate 20, in particular in a method according to any one of the preceding sentences 1 to 12. 15. Use of the method described in any one of the preceding sentences 1 to 12 as a stability test during the development, manufacture, shelf-life or storage of an aqueous formulation or several aqueous formulations each containing polysorbate 20 to determine the degree of oxidative degradation of polysorbate 20 in the aqueous formulation.
Claims
1. 1. A method for determining the extent of oxidative degradation of polysorbate 20 in an aqueous formulation containing polysorbate 20, comprising the steps of: Step 1. Preparing a first sample of the aqueous formulation to be tested, which serves as a reference sample; Step 2 of preparing a second sample of the aqueous formulation to be tested and any further samples; using a liquid chromatography-mass spectrometry based method to separate polyethylene glycol-6-laurate from the reference sample of step 1 and the second sample and each of any further samples of step 2, respectively, and to determine the peak area of polyethylene glycol-6-laurate, which is an oxidation marker of oxidative degradation of Polysorbate 20; determining a relative peak area of polyethylene glycol-6-laurate based on the peak area of polyethylene glycol-6-laurate of the second sample and each of any further samples relative to the peak area of polyethylene glycol-6-laurate of the reference sample, the relative peak area being proportional to the extent of oxidative degradation of Polysorbate 20; and Step 4. Quantify the amount of polyethylene glycol-6-laurate in the second sample and each of any further samples based on the relative peak areas of each sample. The method includes:
2. The prepared reference sample is an aqueous solution containing polysorbate 20, and the content of polysorbate 20 is the same as that of the aqueous formulation to be tested. The method of claim 1.
3. In step 2, two, three or more additional samples of the aqueous formulation containing polysorbate 20 are collected at successive time intervals T1, T2, T3, T4, T5, T6, T7, T8, T9, T10, T11, T12, T13, T14, T15, T16, T17, T18, T19, T20, T21, T22, T23, T24, T25, T26, T27, T28, T29, T30, T31, T32, T33, T34, T35, T36, T37, T38, T39, T40, T41, T42, T43, T44, T45, T46, T47, T48, T49, T41, T42, T43, T44, T45, T46, T47, T48, T49, T49, T50, T51, T52, T53, T54, T55, T56, T57, T58, T59, T60, T61, T62, T63, T64, T65, T66, T67, T68, T69, T69, T70, T71, T72, T73, T74, T75, T76, T77, T78, T79, T80, T81, T82, T83, T84, T85, T86, T87, T88, T89, T90, T91, T92, T93, T94, T95, T96, T97, T98, T99, T90, T91, T91, T92, T93, T94, T95, T96, T97, T98, T99, T99, T Characterized in that the sample is taken at The method of claim 1.
4. The relative peak areas for polyethylene glycol-6-laurate for the second sample from step 3 and for each of the optional further samples are - calculating the difference in the obtained peak areas by subtracting the polyethylene glycol-6-laurate peak area of the reference sample from the polyethylene glycol-6-laurate peak area of the second sample and from the polyethylene glycol-6-laurate peak area of each of any further samples, respectively; or - normalizing the obtained peak areas, by setting the peak area of polyethylene glycol-6-laurate of the reference sample to 100% and calculating and normalizing the peak areas of polyethylene glycol-6-laurate of each of the second sample and any further samples, respectively, on this basis; is determined by The method of claim 1.
5. 1. A method for determining the extent of oxidative degradation of polysorbate 20 in several aqueous formulations each containing polysorbate 20, particularly in several aqueous formulations each containing the same amount of polysorbate 20, comprising the steps of: Step 1a, preparing a sample of each aqueous formulation to be tested; using a liquid chromatography and mass spectrometry based method to separate polyethylene glycol-6-laurate and determine the peak area of polyethylene glycol-6-laurate, an oxidation marker of the oxidative degradation of polysorbate 20, from each sample of step 1a; Step 2a of comparing the peak areas of the samples with each other, the difference in the peak areas of the samples being proportional to the degree of oxidative degradation of polysorbate 20 in each of the samples; and Step 3a. Quantifying the amount of polyethylene glycol-6-laurate in each sample based on the peak area obtained for each sample. The method includes:
6. The relative peak areas of polyethylene glycol-6-laurate in each sample were - calculating the difference in the obtained peak areas by subtracting the peak area of polyethylene glycol-6-laurate of the reference sample from the peak area of polyethylene glycol-6-laurate of each sample of step 2a; or - normalizing the obtained peak areas, by setting the peak area of polyethylene glycol-6-laurate of the reference sample to 100%, and calculating and normalizing the peak area of polyethylene glycol-6-laurate of each sample of step 2a on this basis; is determined relative to a reference sample by The method according to claim 5.
7. The following conditions: - a polar solvent is added to the polysorbate-containing sample to be examined before carrying out liquid chromatography, in particular a solvent used in liquid chromatography; liquid chromatography is used as separation chromatography, in particular in the form of column chromatography, more particularly as reversed-phase chromatography; - liquid chromatography is used as high performance liquid chromatography and gradient elution may be used; - liquid chromatography is used as ultra-performance liquid chromatography and gradient elution may be used; the mass spectrometry method is selected to be a high-resolution mass spectrometry method, in particular for the purpose of structure elucidation; - polyethylene glycol-6-laurate is separated by liquid chromatography using hydrophobicity; and / or - quantification of step 4 or step 3a is carried out with external calibration using standard solutions of polyethylene glycol-6-laurate; The present invention is characterized in that it satisfies one, two or more of the following requirements: The method according to any one of claims 1 to 6.
8. For data evaluation of liquid chromatography-mass spectrometry based methods, extracted ion chromatograms are generated from mass-to-charge ratios that include a range of about 487 amu, in particular a range of 486.5 to 487.5 amu, or consist of this range. The method according to any one of claims 1 to 7.
9. performing an additional step 5 following step 4 or step 3, or an additional step 5' following step 4' or step 3', or an additional step 4a following step 3a or step 2a, each of which comprises estimating the extent to which polysorbate 20 has already been oxidatively degraded in the sample based on the inverse relationship between the polyethylene glycol-6-laurate level and the polysorbate 20 level; The method according to any one of claims 1 to 8.
10. The aqueous biopharmaceutical formulation is used as an aqueous formulation, The method according to any one of claims 1 to 9.
11. The polysorbate 20 present in the sample is - intended for pharmaceutical use, in particular for use in medicine; and / or - suitable for parenteral administration Characterized by: The method according to any one of claims 1 to 10.
12. the aqueous formulation comprises one or more proteins, which may be selected from monoclonal antibodies, polyclonal antibodies, monospecific antibodies, multispecific antibodies, single chain antibodies or antibody fragments thereof, such as Fv, scFv, Fab, Fab', scFab, F(ab')2, Fab2, Fc and Fc' fragments, heavy and light immunoglobulin chains and their constant, variable or hypervariable regions and Fv and Fd fragments, diabodies, triabodies, scFv-Fc, minibodies, or single domain antibodies, or mixtures thereof; Characterized in that the protein can be selected from therapeutic proteins used in the prevention or treatment of a disease or disorder, The method according to any one of claims 1 to 11.
13. A process for producing a recombinant protein comprising the steps of: a) culturing in a cell culture a eukaryotic cell expressing the recombinant protein in cell culture; b) harvesting the recombinant protein; c) purifying the recombinant protein using the aqueous formulation; Step d) of formulating the recombinant protein into a pharma- ceutically acceptable aqueous formulation suitable for administration using polysorbate 20; and e) obtaining at least one sample of the pharma- ceutically acceptable aqueous formulation of step d); Including, 10. The method of claim 1, further comprising carrying out a method for detecting the degree of oxidative degradation of polysorbate 20 according to any one of claims 1 to 9 in a sample obtained in step e), wherein the sample from step d) can be a drug substance sample or a drug product sample. process.
14. Use of polyethylene glycol-6-laurate as an oxidation marker in a method for determining the degree of oxidative degradation of polysorbate 20 in an aqueous formulation or in several aqueous formulations each containing polysorbate 20, in particular in a method according to any one of claims 1 to 12.
15. 13. Use of the method according to any one of claims 1 to 12 as a stability test during development, manufacture, shelf-life or storage of an aqueous formulation or several aqueous formulations, respectively, containing Polysorbate 20, to determine the extent of oxidative degradation of Polysorbate 20 in said aqueous formulation.
Citation Information
Patent Citations
Compositions and methods useful for stabilizing protein-containing formulations
US20170224820A1
Process for polysorbate quantification in a sample involving LC-ms with an internal standard
WO2020174064A1
Methods and compositions comprising reduced level of host cell proteins
WO2021007504A2
